WO2024018955A1 - Oral composition, and method for suppressing bitterness derived from ergothioneine and off-flavor derived from glucosamine compound - Google Patents
Oral composition, and method for suppressing bitterness derived from ergothioneine and off-flavor derived from glucosamine compound Download PDFInfo
- Publication number
- WO2024018955A1 WO2024018955A1 PCT/JP2023/025650 JP2023025650W WO2024018955A1 WO 2024018955 A1 WO2024018955 A1 WO 2024018955A1 JP 2023025650 W JP2023025650 W JP 2023025650W WO 2024018955 A1 WO2024018955 A1 WO 2024018955A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ergothioneine
- glucosamine
- salt
- derived
- compound
- Prior art date
Links
- SSISHJJTAXXQAX-ZETCQYMHSA-N L-ergothioneine Chemical compound C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC(=S)N1 SSISHJJTAXXQAX-ZETCQYMHSA-N 0.000 title claims abstract description 115
- 229940093497 ergothioneine Drugs 0.000 title claims abstract description 110
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 title claims abstract description 73
- 229960002442 glucosamine Drugs 0.000 title claims abstract description 72
- 239000000203 mixture Substances 0.000 title claims abstract description 68
- -1 glucosamine compound Chemical class 0.000 title claims abstract description 41
- 235000019658 bitter taste Nutrition 0.000 title claims abstract description 36
- 239000000796 flavoring agent Substances 0.000 title claims abstract description 8
- 238000000034 method Methods 0.000 title claims description 16
- 150000003839 salts Chemical class 0.000 claims abstract description 74
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims abstract description 39
- 150000002301 glucosamine derivatives Chemical class 0.000 claims description 34
- 235000013305 food Nutrition 0.000 claims description 26
- 150000001875 compounds Chemical class 0.000 claims description 14
- 125000003277 amino group Chemical group 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- 125000002252 acyl group Chemical group 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 239000004615 ingredient Substances 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 description 21
- 229960001911 glucosamine hydrochloride Drugs 0.000 description 21
- 239000003814 drug Substances 0.000 description 18
- 229940079593 drug Drugs 0.000 description 12
- 238000011156 evaluation Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 9
- 210000002105 tongue Anatomy 0.000 description 9
- 239000000047 product Substances 0.000 description 6
- 239000008187 granular material Substances 0.000 description 5
- 230000001766 physiological effect Effects 0.000 description 5
- 235000019643 salty taste Nutrition 0.000 description 5
- 239000000654 additive Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229930014626 natural product Natural products 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 235000019605 sweet taste sensations Nutrition 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 235000019640 taste Nutrition 0.000 description 4
- 240000002769 Morchella esculenta Species 0.000 description 3
- 235000002779 Morchella esculenta Nutrition 0.000 description 3
- 240000001462 Pleurotus ostreatus Species 0.000 description 3
- 235000001603 Pleurotus ostreatus Nutrition 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000019606 astringent taste Nutrition 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 244000251953 Agaricus brunnescens Species 0.000 description 2
- 241000238557 Decapoda Species 0.000 description 2
- 240000008397 Ganoderma lucidum Species 0.000 description 2
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 240000001080 Grifola frondosa Species 0.000 description 2
- 235000007710 Grifola frondosa Nutrition 0.000 description 2
- 240000000588 Hericium erinaceus Species 0.000 description 2
- 235000007328 Hericium erinaceus Nutrition 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 240000000599 Lentinula edodes Species 0.000 description 2
- 235000001715 Lentinula edodes Nutrition 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 102000016387 Pancreatic elastase Human genes 0.000 description 2
- 108010067372 Pancreatic elastase Proteins 0.000 description 2
- 241000222350 Pleurotus Species 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000004900 autophagic degradation Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000003925 brain function Effects 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 150000002337 glycosamines Chemical class 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000008099 melanin synthesis Effects 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- 150000002823 nitrates Chemical class 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000007665 sagging Methods 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- 230000037373 wrinkle formation Effects 0.000 description 2
- LDDMACCNBZAMSG-BDVNFPICSA-N (2r,3r,4s,5r)-3,4,5,6-tetrahydroxy-2-(methylamino)hexanal Chemical compound CN[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO LDDMACCNBZAMSG-BDVNFPICSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 244000045069 Agrocybe aegerita Species 0.000 description 1
- 235000008121 Agrocybe aegerita Nutrition 0.000 description 1
- 241000404030 Anacyclus clavatus Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000222455 Boletus Species 0.000 description 1
- 241001489124 Boletus edulis Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 244000191482 Cantharellus cibarius Species 0.000 description 1
- 235000015722 Cantharellus cibarius Nutrition 0.000 description 1
- 241000238366 Cephalopoda Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000239366 Euphausiacea Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- FZHXIRIBWMQPQF-UHFFFAOYSA-N Glc-NH2 Natural products O=CC(N)C(O)C(O)C(O)CO FZHXIRIBWMQPQF-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 208000007353 Hip Osteoarthritis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000392443 Pleurotus citrinopileatus Species 0.000 description 1
- 235000007685 Pleurotus columbinus Nutrition 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000121220 Tricholoma matsutake Species 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- FZHXIRIBWMQPQF-SLPGGIOYSA-N aldehydo-D-glucosamine Chemical compound O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO FZHXIRIBWMQPQF-SLPGGIOYSA-N 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 150000004701 malic acid derivatives Chemical class 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Definitions
- the present invention relates to an oral composition containing ergothioneine or a salt thereof and a glucosamine compound.
- the present invention also relates to a method for suppressing the bitter taste derived from ergothioneine and the off-taste derived from glucosamine compounds.
- Ergothioneine is one of the hydrophilic sulfur-containing amino acids and is known to have various physiological activities including antioxidant ability.
- Patent Document 1 reports an immune response-activating cytokine production promoting effect. Since ergothioneine has a variety of physiological activities, it has recently attracted attention as a food, cosmetic, and pharmaceutical product.
- Glucosamine is an amino sugar in which the hydroxyl group at the 2-position of glucose is replaced with an amino group.
- Glucosamine is a component of cartilage, which is a tissue that absorbs shock in joints, and is used in health foods to improve symptoms such as osteoarthritis.
- ergothioneine since ergothioneine has useful physiological activity, foods such as supplements containing ergothioneine or its salt are useful for maintaining or promoting health.
- ergothioneine or its salt has a unique flavor, especially a bitter taste that stings the tongue, and there is room for improvement in making it into an oral composition.
- glucosamine has a unique off-taste, specifically a salty taste, a sweet taste that lingers on the tongue, and an astringent taste, and when incorporated into an oral composition, the unique off-taste may become a problem.
- An object of the present invention is to provide an oral composition containing ergothioneine or a salt thereof and a glucosamine compound, but in which the bitter taste derived from ergothioneine or its salt and the off-taste derived from the glucosamine compound are suppressed.
- Another object of the present invention is to provide a method for suppressing the bitter taste derived from ergothioneine or its salt and the off-taste derived from glucosamine compounds.
- the present inventors found that by combining ergothioneine or its salt and glucosamine compound in a specific ratio, the bitterness derived from ergothioneine or its salt and the glucosamine compound can be reduced. It has been found that it is possible to suppress off-taste (salty taste, sweet taste that remains on the tongue, and peculiar off-taste accompanied by acrid taste).
- the present invention includes the following compositions.
- the glucosamine compound is at least one selected from the group consisting of glucosamine, derivatives thereof, and salts thereof.
- a derivative of glucosamine is a compound in which the hydrogen atom of at least one hydroxyl group and/or the hydrogen atom of an amino group of glucosamine is substituted with an acyl group and/or alkyl group having 1 to 10 carbon atoms, [1 ] or the composition according to [2].
- [5] The following components (A) and (B): In an oral composition containing (A) ergothioneine or a salt thereof, and (B) a glucosamine compound, the weight ratio of component (B) (in terms of glucosamine) to component (A) (in terms of ergothioneine) ((B) /(A)) to 0.2 to 150, a method for suppressing bitterness derived from ergothioneine or a salt thereof and off-taste derived from glucosamine compounds.
- an oral composition containing ergothioneine or a salt thereof and a glucosamine compound but in which the bitter taste derived from ergothioneine or its salt and the off-taste derived from the glucosamine compound are suppressed.
- a method for suppressing the bitter taste derived from ergothioneine or its salt and the off-taste derived from glucosamine compounds it is possible to provide a method for suppressing the bitter taste derived from ergothioneine or its salt and the off-taste derived from glucosamine compounds.
- the oral composition of the present invention contains (A) ergothioneine or a salt thereof, and (B) a glucosamine compound, and the weight ratio of component (B) (in terms of glucosamine) to component (A) (in terms of ergothioneine). ((B)/(A)) is 0.2 to 150.
- Ergothioneine is a type of sulfur-containing amino acid.
- ergothioneine is preferably L-ergothioneine.
- the salt of ergothioneine is not particularly limited as long as it is a pharmacologically acceptable salt or a salt acceptable for foods and drinks, and may be either an acidic salt or a basic salt.
- Acid salts include, for example, inorganic acid salts such as hydrochlorides, sulfates, nitrates, phosphates; acetates, citrates, maleates, malates, oxalates, lactates, succinates, fumarates; Examples include organic acid salts such as acid salts and propionate salts.
- Examples of basic salts include alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts and magnesium salts.
- Ergothioneine or its salt is not limited in any way by its form or manufacturing method. Ergothioneine or a salt thereof may be a chemically synthesized product or may be extracted and purified from a natural product. L-ergothioneine is abundantly contained in Golden/Yellow Oyster Mushroom (scientific name: Pleurotus cornucopiae var. citrinopileatus), which is a mushroom of the Pleurotus family and Pleurotus genus.
- L-ergothioneine is extracted from Agaricus bisporus (scientific name: Agaricus bisporus), Gray Oyster Mushroom (scientific name: Pleurotus ostreatus), such as white button mushrooms, crimini mushrooms, and Portabella mushrooms.
- shiitake (scientific name: Lentinula edodes), maitake (scientific name: Grifola frondosa), Reishi (scientific name: Ganoderma lucidum), Hericium erinaceus (scientific name: Hericium erinaceus), Willow matsutake (scientific name: Agrocybe aegerita), Chanterelle (scientific name: Ca) ntharellus cibarius), boletus (scientific name: Boletus edulis), morel mushroom ( It is also included in mushrooms such as Morchella esculenta (scientific name: Morchella esculenta).
- L-ergothioneine is obtained from a natural product, it is preferably extracted from Tamogitake mushrooms. Ergothioneine or its salt can also be produced by microbial fermentation. Ergothioneine or a salt thereof may be isolated.
- Glucosamine (2-amino-2-deoxy-D-glucose) is an amino sugar in which the hydroxyl group at the 2-position of glucose is replaced with an amino group, and in the animal body, it is widely used as a component of mucopolysaccharide in cartilage and connective tissue. It is distributed. Glucosamine has a unique off-taste, with a salty taste, a sweet taste that lingers on the tongue, and an astringent taste. By containing the glucosamine compound, the composition of the present invention has reduced bitterness derived from ergothioneine or a salt thereof.
- glucosamine compound By combining a glucosamine compound and ergothioneine or a salt thereof, it is also possible to suppress the salty taste derived from the glucosamine compound, the sweet taste that remains on the tongue, and the characteristic off-taste associated with astringency. Therefore, continuous intake of ergothioneine or its salt and glucosamine compounds becomes easy.
- the glucosamine compound is a general term for compounds including glucosamine, derivatives thereof, and salts thereof.
- glucosamine derivatives include, but are not particularly limited to, compounds in which the hydroxyl group of glucosamine is esterified or etherified, compounds in which the amino group is acylated, and the like.
- the glucosamine derivative is preferably a compound in which at least one hydrogen atom of a hydroxyl group and/or a hydrogen atom of an amino group of glucosamine is substituted with an acyl group and/or an alkyl group having 1 to 10 carbon atoms. More preferred is a compound in which the hydrogen atom of the amino group of glucosamine is substituted with an acyl group or alkyl group having 1 to 10 carbon atoms.
- the number of carbon atoms in the acyl group and/or alkyl group is preferably 1 to 8, more preferably 1 to 5, still more preferably 1 to 3, and particularly preferably 2.
- Specific examples of the acyl group include formyl group, acetyl group, propionyl group, and benzoyl group. More preferred glucosamine derivatives are N-acetylglucosamine and N-methyl-L-glucosamine, and particularly preferred is N-acetylglucosamine.
- Salts of glucosamine and its derivatives are not particularly limited as long as they are pharmacologically acceptable salts or salts that are acceptable for food and beverages, but include inorganic acids such as hydrochlorides, sulfates, nitrates, and phosphates. Salts; organic acid salts such as acetate, citrate, maleate, malate, oxalate, lactate, succinate, fumarate, propionate, and the like. Preferably it is an inorganic acid salt, more preferably a hydrochloride.
- the glucosamine compound used in the present invention is not limited in any way by its form or manufacturing method, and commercially available products may be used, or those extracted and purified from natural products may be used.
- glucosamine it can be obtained by hydrolyzing chitin contained in crustaceans such as crabs, shrimps, and krill, and cartilage of squid using acids or enzymes, followed by separation and purification.
- the weight ratio of component (B) (in terms of glucosamine) to component (A) (in terms of ergothioneine) ((B) in terms of glucosamine/(A) in terms of ergothioneine) is 0.2 to 150. It is. Ergothioneine or its salts have a bitter taste that stings the tongue. Glucosamine compounds also have a unique off-taste. In a composition containing components (A) and (B), the weight ratio ((B)/(A)) of component (B) (in terms of glucosamine) to component (A) (in terms of ergothioneine) is within the above range.
- the weight ratio ((B)/(A)) is preferably 0.4 to 130, more preferably 0.5 to 120, even more preferably 1 to 100, particularly preferably 5 to 80. and most preferably 10-50.
- the content of ergothioneine or its salt contained in the composition of the present invention is not particularly limited, and can be set depending on its form and the like.
- the content of ergothioneine or its salt in the composition of the present invention is preferably 0.1% by weight or more, more preferably 0.5% by weight or more, and 0.6% by weight in terms of ergothioneine. % or more, still more preferably 0.8% by weight or more, particularly preferably 1% by weight or more, and preferably 50% by weight or less, more preferably 40% by weight or less, even more preferably 30% by weight or less, It is even more preferably 20% by weight or less, particularly preferably 10% by weight or less.
- the content of ergothioneine or a salt thereof in the composition of the present invention is preferably 0.1 to 50% by weight, more preferably 0.5 to 40% by weight, and 0.6 to 30% by weight in terms of ergothioneine. % by weight is more preferred, 0.8 to 20% by weight is even more preferred, and 1 to 10% by weight is particularly preferred.
- the composition of the present invention contains two or more compounds as ergothioneine or its salt
- the content of ergothioneine or its salt is the total content thereof.
- the content of ergothioneine can be measured by high performance liquid chromatography (HPLC).
- the amount of ergothioneine or a salt thereof in terms of ergothioneine or a similar expression means, in the case of ergothioneine, the amount.
- a salt of ergothioneine it means the value obtained by multiplying the number of moles of the salt by the molecular weight of ergothioneine.
- the content of glucosamine compounds contained in the composition of the present invention is not particularly limited, and can be set depending on its form and the like.
- the content of glucosamine compounds in the composition of the present invention is, in terms of glucosamine, preferably 0.02% by weight or more, more preferably 0.1% by weight or more, and 1% by weight or more in the composition. More preferably, 5% by weight or more, even more preferably 10% by weight or more, even more preferably 20% by weight or more, particularly preferably 30% by weight or more, particularly still more preferably 40% by weight or more, and 99% by weight or more.
- the content of the glucosamine compound in the composition of the present invention is preferably 0.02 to 99% by weight, more preferably 0.1 to 99% by weight, and 1 to 99% by weight in terms of glucosamine. is even more preferred, 5 to 95% by weight is even more preferred, 10 to 90% by weight is even more preferred, 20 to 80% by weight is even more preferred, 30 to 70% by weight is particularly preferred, and 40 to 60% by weight is even more particularly preferred. preferable.
- glucosamine compounds When two or more kinds of compounds are contained as glucosamine compounds, the above content is the total content thereof.
- the content of glucosamine compounds can be measured by HPLC method.
- the amount of a glucosamine compound in terms of glucosamine or a similar expression means the amount in the case of glucosamine. In the case of a compound other than glucosamine, it means the value obtained by multiplying the number of moles of the compound by the molecular weight of glucosamine.
- the content of ergothioneine or its salt is preferably 1 to 100 mg, more preferably 2 to 50 mg, and more preferably 5 to 25 mg in terms of ergothioneine per daily intake for adults. More preferably, the amount is 5 to 20 mg, particularly preferably 5 to 20 mg.
- the content of glucosamine compounds is preferably 10 to 5000 mg, more preferably 20 to 3000 mg, and more preferably 50 to 2000 mg in terms of glucosamine per daily intake for adults. More preferably.
- Ergothioneine or its salts and glucosamine compounds are compounds that are contained in natural products and food and drink products and have been eaten. Therefore, from the viewpoint of safety, ergothioneine or its salts and glucosamine compounds are considered to pose few problems when ingested, for example, every day. According to the present invention, it is possible to provide a composition that is highly safe, has reduced bitterness derived from ergothioneine or its salt, and reduced off-taste derived from glucosamine compounds, and is easy to ingest.
- composition of the present invention can be used for antioxidant purposes, for improving brain function, for anti-aging, for eye diseases, for whitening, for absorbing ultraviolet rays, for suppressing melanin production, for eliminating reactive oxygen species, and for inhibiting elastase activity. It can be suitably used for suppressing wrinkle formation, suppressing skin sagging, promoting autophagy, etc.
- Glucosamine compounds are known to exert health functions such as improving pain caused by knee osteoarthritis and hip osteoarthritis. Since the composition of the present invention contains glucosamine compounds, it can also be used to obtain the above effects exerted by these compounds.
- compositions of the invention can be applied for either therapeutic (medical) or non-therapeutic (non-medical) uses.
- Non-therapeutic is a concept that does not include medical procedures, ie, surgery, treatment, or diagnosis of humans.
- the composition of the present invention can be in the form of a food or drink, a drug, a quasi-drug, a feed, or the like.
- the composition of the present invention may be a material or a preparation used by being mixed into foods and drinks, pharmaceuticals, quasi-drugs, feeds, and the like.
- the composition of the present invention is a composition for oral use, and specific examples of the oral composition include food and drink products, oral drugs, quasi-drugs, feeds, etc., and preferably food and drink products or oral compositions. It is a medicine, and more preferably a food or drink.
- the composition of the present invention may contain arbitrary additives and arbitrary components in addition to ergothioneine or a salt thereof and a glucosamine compound, as long as the effects of the present invention are not impaired.
- additives and components can be selected depending on the form of the composition, etc., and those that can be generally used in oral compositions such as foods and drinks, pharmaceuticals, quasi-drugs, and feeds can be used.
- the manufacturing method thereof is not particularly limited, and it can be manufactured by a general method.
- the composition of the present invention may consist of ergothioneine or a salt thereof and a glucosamine compound.
- the form of the oral composition of the present invention is not particularly limited, and may be solid (powder, granule, tablet, etc.), liquid, paste, or the like.
- composition of the present invention when used as a food or drink, ingredients that can be used in food or drink (e.g., food materials, food additives used as necessary, etc.) are added to ergothioneine or its salt and glucosamine compounds. It can be made into various food and drink products.
- Foods and drinks are not particularly limited, and include, for example, general foods and drinks, health foods, health supplements, health drinks, foods with functional claims, foods for specified health uses, foods and drinks for patients, and the like.
- the above health foods, health supplements, foods with functional claims, foods for specified health uses, etc. include fine granules, tablets, granules, powders, capsules, chewables, dry syrups, syrups, liquids, beverages, and drinks. It can be used in various formulations such as tablets and liquid foods.
- composition of the present invention when used as a drug or quasi-drug, for example, ergothioneine or a salt thereof and a glucosamine compound are mixed with a pharmacologically acceptable carrier, additives added as necessary, etc. It can be used as pharmaceuticals or quasi-drugs in various dosage forms.
- Such carriers, additives, etc. may be pharmacologically acceptable ones that can be used in pharmaceuticals or quasi-drugs, such as excipients, binders, disintegrants, lubricants, One or more of antioxidants, colorants, etc. may be used.
- Dosage forms for oral administration of pharmaceuticals or quasi-drugs include liquids, tablets, powders, fine granules, granules, sugar-coated tablets, capsules, suspensions, emulsions, chewables, and the like.
- feed When the composition of the present invention is used as feed, ergothioneine or a salt thereof and a glucosamine compound may be added to the feed.
- Feed also includes feed additives. Examples of the feed include livestock feed for cows, pigs, chickens, sheep, horses, etc.; small animal feed for rabbits, rats, mice, etc.; pet foods for dogs, cats, small birds, etc.
- composition of the present invention is ingested or administered (also referred to as the subject of administration) is not particularly limited.
- it is a human or non-human mammal, more preferably a human.
- the present invention also includes the following method.
- an oral composition containing (A) ergothioneine or a salt thereof, and (B) a glucosamine compound, the weight ratio of component (B) (in terms of glucosamine) to component (A) (in terms of ergothioneine) ((B) /(A)) to 0.2 to 150, a method for suppressing bitterness derived from ergothioneine or a salt thereof and off-taste derived from glucosamine compounds.
- component (B) in terms of glucosamine
- component (A) in terms of ergothioneine
- ergothioneine or a salt thereof can be obtained. It is possible to obtain an oral composition in which the bitter taste derived from glucosamine compounds and the off-taste derived from glucosamine compounds are suppressed.
- the above method makes it possible to effectively suppress the bitter taste derived from ergothioneine or its salt and the off-taste derived from glucosamine compounds.
- the taste of the oral composition can be improved.
- ergothioneine or a salt thereof, glucosamine compounds, and preferred embodiments thereof are the same as in the oral composition of the present invention described above.
- the preferred range of the weight ratio ((B)/(A)) of component (B) (in terms of glucosamine) to component (A) (in terms of ergothioneine) is also the same as in the oral composition of the present invention.
- the above method can suppress the bitter taste derived from ergothioneine or its salt and the off-taste derived from glucosamine compounds, other methods may be combined to suppress these unpleasant flavors.
- Other suppression methods include, for example, adding sweeteners or flavoring agents to ingredients with unpleasant flavors to formulate formulations, coating the ingredients with sugar to formulate formulations, or encapsulating the ingredients in capsules. Examples include methods for formulating formulations.
- Glucosamine compounds are useful for suppressing the bitter taste of ergothioneine or its salt.
- the present invention also includes the use of (B) a glucosamine compound to suppress the bitter taste derived from (A) ergothioneine or a salt thereof.
- the amount of glucosamine compounds to be used is such that the weight ratio ((B)/(A)) of (B) glucosamine compounds (in terms of glucosamine) to (A) ergothioneine or its salt (in terms of ergothioneine) is 0.2 or more.
- the amount is preferable, and the amount such that the above weight ratio is 0.2 to 150 is more preferable.
- Ergothioneine or a salt thereof is useful for suppressing the off-taste of glucosamine compounds.
- the present invention also includes the use of (A) ergothioneine or a salt thereof to suppress the off-taste derived from (B) glucosamine compounds.
- the amount of ergothioneine or its salt to be used is such that the weight ratio ((B)/(A)) of (B) glucosamine compound (in terms of glucosamine) to (A) ergothioneine or its salt (in terms of ergothioneine) is 0.2 or more.
- the amount is preferably such that the above weight ratio is 0.2 to 150.
- the numerical range expressed by a lower limit value and an upper limit value includes the lower limit value and upper limit value.
- the range represented by "1 to 2" means 1 or more and 2 or less, and includes 1 and 2.
- the upper limit and the lower limit may be any combination of ranges.
- Example 1 Flavor evaluation test for a composition containing ergothioneine and glucosamine hydrochloride> A composition containing ergothioneine and glucosamine hydrochloride was prepared, and three panelists skilled in sensory evaluation performed sensory evaluation. Compositions of Samples 1 to 9 (compositions containing ergothioneine and glucosamine hydrochloride) were prepared by mixing the amounts of (A) and (B) shown in Table 1. Table 1 shows the weight ratios of (B)/(A) ((B)/(A) in terms of glucosamine) in the compositions of Samples 1 to 9.
- Three panelists each placed the entire amount of the prepared composition (for example, in sample 1, 10 mg of ergothioneine and 1 mg of glucosamine hydrochloride, total 11 mg) on their tongues, and evaluated the intensity of bitterness derived from ergothioneine and the intensity of bitterness derived from glucosamine hydrochloride.
- the intensity of off-taste was evaluated according to the following criteria.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention addresses the problem of providing an oral composition which contains ergothioneine or a salt thereof and a glucosamine compound and yet in which the bitterness derived from ergothioneine or the salt thereof and the off-flavor derived from the glucosamine compound are suppressed. The present invention relates to an oral composition containing the following components (A) and (B): (A) ergothioneine or a salt thereof; and (B) a glucosamine compound, wherein the weight ratio [(B)/(A)] of component (B) (in terms of glucosamine) to component (A) (in terms of ergothioneine) is 0.2-150.
Description
本発明は、エルゴチオネイン又はその塩及びグルコサミン類化合物を含有する経口組成物に関する。また、本発明は、エルゴチオネインに由来する苦味及びグルコサミン類化合物に由来する異味を抑制する方法に関する。
The present invention relates to an oral composition containing ergothioneine or a salt thereof and a glucosamine compound. The present invention also relates to a method for suppressing the bitter taste derived from ergothioneine and the off-taste derived from glucosamine compounds.
エルゴチオネインは、親水性含硫アミノ酸の一つであり、抗酸化能をはじめとする多様な生理活性を有することが知られている。エルゴチオネインの生理活性に関して、例えば、特許文献１には免疫応答活性化サイトカイン産生促進作用などが報告されている。
エルゴチオネインは、多様な生理活性を有することから、近年、食品用、化粧品用や医薬用として注目されている。 Ergothioneine is one of the hydrophilic sulfur-containing amino acids and is known to have various physiological activities including antioxidant ability. Regarding the physiological activity of ergothioneine, for example, Patent Document 1 reports an immune response-activating cytokine production promoting effect.
Since ergothioneine has a variety of physiological activities, it has recently attracted attention as a food, cosmetic, and pharmaceutical product.
エルゴチオネインは、多様な生理活性を有することから、近年、食品用、化粧品用や医薬用として注目されている。 Ergothioneine is one of the hydrophilic sulfur-containing amino acids and is known to have various physiological activities including antioxidant ability. Regarding the physiological activity of ergothioneine, for example, Patent Document 1 reports an immune response-activating cytokine production promoting effect.
Since ergothioneine has a variety of physiological activities, it has recently attracted attention as a food, cosmetic, and pharmaceutical product.
グルコサミンは、グルコースの２位の水酸基がアミノ基に置換したアミノ糖である。グルコサミンは、関節の衝撃を吸収する組織である軟骨の構成要素であり、変形性関節症等の症状改善のための健康食品等に使用されている。
Glucosamine is an amino sugar in which the hydroxyl group at the 2-position of glucose is replaced with an amino group. Glucosamine is a component of cartilage, which is a tissue that absorbs shock in joints, and is used in health foods to improve symptoms such as osteoarthritis.
上述のとおり、エルゴチオネインは有用な生理活性を有しているため、エルゴチオネイン又はその塩を含むサプリメント等の食品は、健康維持又は増進に有用である。しかしながら、エルゴチオネイン又はその塩には独特の香味、特に舌を刺すような苦味（苦み）があり、経口組成物とするうえで改善する余地があった。
また、グルコサミンには特有の異味、具体的には、塩味、舌に残る甘味、えぐみを伴う特有の異味があり、経口組成物に配合すると当該特有の異味が問題となる場合がある。 As mentioned above, since ergothioneine has useful physiological activity, foods such as supplements containing ergothioneine or its salt are useful for maintaining or promoting health. However, ergothioneine or its salt has a unique flavor, especially a bitter taste that stings the tongue, and there is room for improvement in making it into an oral composition.
In addition, glucosamine has a unique off-taste, specifically a salty taste, a sweet taste that lingers on the tongue, and an astringent taste, and when incorporated into an oral composition, the unique off-taste may become a problem.
また、グルコサミンには特有の異味、具体的には、塩味、舌に残る甘味、えぐみを伴う特有の異味があり、経口組成物に配合すると当該特有の異味が問題となる場合がある。 As mentioned above, since ergothioneine has useful physiological activity, foods such as supplements containing ergothioneine or its salt are useful for maintaining or promoting health. However, ergothioneine or its salt has a unique flavor, especially a bitter taste that stings the tongue, and there is room for improvement in making it into an oral composition.
In addition, glucosamine has a unique off-taste, specifically a salty taste, a sweet taste that lingers on the tongue, and an astringent taste, and when incorporated into an oral composition, the unique off-taste may become a problem.
本発明の目的は、エルゴチオネイン又はその塩及びグルコサミン類化合物を含有しながらも、エルゴチオネイン又はその塩に由来する苦味及びグルコサミン類化合物に由来する異味が抑制された経口組成物を提供することである。また、本発明は、エルゴチオネイン又はその塩に由来する苦味及びグルコサミン類化合物に由来する異味を抑制する方法を提供することを目的とする。
An object of the present invention is to provide an oral composition containing ergothioneine or a salt thereof and a glucosamine compound, but in which the bitter taste derived from ergothioneine or its salt and the off-taste derived from the glucosamine compound are suppressed. Another object of the present invention is to provide a method for suppressing the bitter taste derived from ergothioneine or its salt and the off-taste derived from glucosamine compounds.
本発明者らは上記課題を解決すべく鋭意研究した結果、エルゴチオネイン又はその塩と、グルコサミン類化合物とを特定の比率で組み合わせることによって、エルゴチオネイン又はその塩に由来する苦味及びグルコサミン類化合物に由来する異味（塩味、舌に残る甘味、えぐみを伴う特有の異味）を抑制することができることを見出した。
As a result of intensive research to solve the above problems, the present inventors found that by combining ergothioneine or its salt and glucosamine compound in a specific ratio, the bitterness derived from ergothioneine or its salt and the glucosamine compound can be reduced. It has been found that it is possible to suppress off-taste (salty taste, sweet taste that remains on the tongue, and peculiar off-taste accompanied by acrid taste).
本発明は、以下の組成物等を包含する。
〔１〕下記の成分（Ａ）及び（Ｂ）：
（Ａ）エルゴチオネイン又はその塩、及び、（Ｂ）グルコサミン類化合物、を含有し、成分（Ａ）（エルゴチオネイン換算）に対する、成分（Ｂ）（グルコサミン換算）の重量比（（Ｂ）／（Ａ））が０．２～１５０である、経口組成物。
〔２〕グルコサミン類化合物は、グルコサミン、その誘導体及びそれらの塩からなる群より選択される少なくとも１種である、〔１〕に記載の組成物。
〔３〕グルコサミンの誘導体は、グルコサミンの少なくとも１つの水酸基の水素原子及び／又はアミノ基の水素原子が、炭素数１～１０のアシル基及び／又はアルキル基に置換された化合物である、〔１〕又は〔２〕に記載の組成物。
〔４〕飲食品である、〔１〕～〔３〕のいずれかに記載の組成物。
〔５〕下記の成分（Ａ）及び（Ｂ）：
（Ａ）エルゴチオネイン又はその塩、及び、（Ｂ）グルコサミン類化合物、を含有する経口組成物において、成分（Ａ）（エルゴチオネイン換算）に対する、成分（Ｂ）（グルコサミン換算）の重量比（（Ｂ）／（Ａ））を０．２～１５０に調整する、エルゴチオネイン又はその塩に由来する苦味及びグルコサミン類化合物に由来する異味を抑制する方法。 The present invention includes the following compositions.
[1] The following components (A) and (B):
Contains (A) ergothioneine or a salt thereof, and (B) a glucosamine compound, and the weight ratio of component (B) (in terms of glucosamine) to component (A) (in terms of ergothioneine) ((B)/(A) ) is 0.2 to 150.
[2] The composition according to [1], wherein the glucosamine compound is at least one selected from the group consisting of glucosamine, derivatives thereof, and salts thereof.
[3] A derivative of glucosamine is a compound in which the hydrogen atom of at least one hydroxyl group and/or the hydrogen atom of an amino group of glucosamine is substituted with an acyl group and/or alkyl group having 1 to 10 carbon atoms, [1 ] or the composition according to [2].
[4] The composition according to any one of [1] to [3], which is a food or drink.
[5] The following components (A) and (B):
In an oral composition containing (A) ergothioneine or a salt thereof, and (B) a glucosamine compound, the weight ratio of component (B) (in terms of glucosamine) to component (A) (in terms of ergothioneine) ((B) /(A)) to 0.2 to 150, a method for suppressing bitterness derived from ergothioneine or a salt thereof and off-taste derived from glucosamine compounds.
〔１〕下記の成分（Ａ）及び（Ｂ）：
（Ａ）エルゴチオネイン又はその塩、及び、（Ｂ）グルコサミン類化合物、を含有し、成分（Ａ）（エルゴチオネイン換算）に対する、成分（Ｂ）（グルコサミン換算）の重量比（（Ｂ）／（Ａ））が０．２～１５０である、経口組成物。
〔２〕グルコサミン類化合物は、グルコサミン、その誘導体及びそれらの塩からなる群より選択される少なくとも１種である、〔１〕に記載の組成物。
〔３〕グルコサミンの誘導体は、グルコサミンの少なくとも１つの水酸基の水素原子及び／又はアミノ基の水素原子が、炭素数１～１０のアシル基及び／又はアルキル基に置換された化合物である、〔１〕又は〔２〕に記載の組成物。
〔４〕飲食品である、〔１〕～〔３〕のいずれかに記載の組成物。
〔５〕下記の成分（Ａ）及び（Ｂ）：
（Ａ）エルゴチオネイン又はその塩、及び、（Ｂ）グルコサミン類化合物、を含有する経口組成物において、成分（Ａ）（エルゴチオネイン換算）に対する、成分（Ｂ）（グルコサミン換算）の重量比（（Ｂ）／（Ａ））を０．２～１５０に調整する、エルゴチオネイン又はその塩に由来する苦味及びグルコサミン類化合物に由来する異味を抑制する方法。 The present invention includes the following compositions.
[1] The following components (A) and (B):
Contains (A) ergothioneine or a salt thereof, and (B) a glucosamine compound, and the weight ratio of component (B) (in terms of glucosamine) to component (A) (in terms of ergothioneine) ((B)/(A) ) is 0.2 to 150.
[2] The composition according to [1], wherein the glucosamine compound is at least one selected from the group consisting of glucosamine, derivatives thereof, and salts thereof.
[3] A derivative of glucosamine is a compound in which the hydrogen atom of at least one hydroxyl group and/or the hydrogen atom of an amino group of glucosamine is substituted with an acyl group and/or alkyl group having 1 to 10 carbon atoms, [1 ] or the composition according to [2].
[4] The composition according to any one of [1] to [3], which is a food or drink.
[5] The following components (A) and (B):
In an oral composition containing (A) ergothioneine or a salt thereof, and (B) a glucosamine compound, the weight ratio of component (B) (in terms of glucosamine) to component (A) (in terms of ergothioneine) ((B) /(A)) to 0.2 to 150, a method for suppressing bitterness derived from ergothioneine or a salt thereof and off-taste derived from glucosamine compounds.
本発明によれば、エルゴチオネイン又はその塩及びグルコサミン類化合物を含有しながらも、エルゴチオネイン又はその塩に由来する苦味及びグルコサミン類化合物に由来する異味が抑制された経口組成物を提供することができる。また、本発明によれば、エルゴチオネイン又はその塩に由来する苦味及びグルコサミン類化合物に由来する異味を抑制する方法を提供することができる。
According to the present invention, it is possible to provide an oral composition containing ergothioneine or a salt thereof and a glucosamine compound, but in which the bitter taste derived from ergothioneine or its salt and the off-taste derived from the glucosamine compound are suppressed. Further, according to the present invention, it is possible to provide a method for suppressing the bitter taste derived from ergothioneine or its salt and the off-taste derived from glucosamine compounds.
本発明の経口組成物は、（Ａ）エルゴチオネイン又はその塩、及び、（Ｂ）グルコサミン類化合物、を含有し、成分（Ａ）（エルゴチオネイン換算）に対する、成分（Ｂ）（グルコサミン換算）の重量比（（Ｂ）／（Ａ））が０．２～１５０である。
The oral composition of the present invention contains (A) ergothioneine or a salt thereof, and (B) a glucosamine compound, and the weight ratio of component (B) (in terms of glucosamine) to component (A) (in terms of ergothioneine). ((B)/(A)) is 0.2 to 150.
エルゴチオネインは、含硫アミノ酸の一種である。本発明において、エルゴチオネインは、好ましくはＬ－エルゴチオネインである。
エルゴチオネインの塩としては、薬理学的に許容される塩又は飲食品に許容される塩であれば特に限定されず、酸性塩及び塩基性塩のいずれであってもよい。酸性塩として、例えば、塩酸塩、硫酸塩、硝酸塩、リン酸塩等の無機酸塩；酢酸塩、クエン酸塩、マレイン酸塩、リンゴ酸塩、シュウ酸塩、乳酸塩、コハク酸塩、フマル酸塩、プロピオン酸塩等の有機酸塩等が挙げられる。塩基性塩として、例えば、ナトリウム塩、カリウム塩等のアルカリ金属塩；カルシウム塩、マグネシウム塩等のアルカリ土類金属塩等が挙げられる。 Ergothioneine is a type of sulfur-containing amino acid. In the present invention, ergothioneine is preferably L-ergothioneine.
The salt of ergothioneine is not particularly limited as long as it is a pharmacologically acceptable salt or a salt acceptable for foods and drinks, and may be either an acidic salt or a basic salt. Acid salts include, for example, inorganic acid salts such as hydrochlorides, sulfates, nitrates, phosphates; acetates, citrates, maleates, malates, oxalates, lactates, succinates, fumarates; Examples include organic acid salts such as acid salts and propionate salts. Examples of basic salts include alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts and magnesium salts.
エルゴチオネインの塩としては、薬理学的に許容される塩又は飲食品に許容される塩であれば特に限定されず、酸性塩及び塩基性塩のいずれであってもよい。酸性塩として、例えば、塩酸塩、硫酸塩、硝酸塩、リン酸塩等の無機酸塩；酢酸塩、クエン酸塩、マレイン酸塩、リンゴ酸塩、シュウ酸塩、乳酸塩、コハク酸塩、フマル酸塩、プロピオン酸塩等の有機酸塩等が挙げられる。塩基性塩として、例えば、ナトリウム塩、カリウム塩等のアルカリ金属塩；カルシウム塩、マグネシウム塩等のアルカリ土類金属塩等が挙げられる。 Ergothioneine is a type of sulfur-containing amino acid. In the present invention, ergothioneine is preferably L-ergothioneine.
The salt of ergothioneine is not particularly limited as long as it is a pharmacologically acceptable salt or a salt acceptable for foods and drinks, and may be either an acidic salt or a basic salt. Acid salts include, for example, inorganic acid salts such as hydrochlorides, sulfates, nitrates, phosphates; acetates, citrates, maleates, malates, oxalates, lactates, succinates, fumarates; Examples include organic acid salts such as acid salts and propionate salts. Examples of basic salts include alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts and magnesium salts.
エルゴチオネイン又はその塩は、その形態や製造方法等によって、何ら制限されるものではない。エルゴチオネイン又はその塩は、化学合成品でもよく、天然物から抽出及び精製されたものでもよい。Ｌ－エルゴチオネインは、ヒラタケ科ヒラタケ属のキノコであるタモギタケ（Ｇｏｌｄｅｎ／Ｙｅｌｌｏｗ Ｏｙｓｔｅｒ Ｍｕｓｈｒｏｏｍ）（学名：Ｐｌｅｕｒｏｔｕｓ ｃｏｒｎｕｃｏｐｉａｅ ｖａｒ． ｃｉｔｒｉｎｏｐｉｌｅａｔｕｓ）に多く含有される。Ｌ－エルゴチオネインは、ホワイトボタンマッシュルーム、クリミニマッシュルーム、ポータベラ（Ｐｏｒｔａｂｅｌｌａ）マッシュルーム等のツクリタケ（学名：Ａｇａｒｉｃｕｓ ｂｉｓｐｏｒｕｓ）、ヒラタケ（Ｇｒｅｙ Ｏｙｓｔｅｒ Ｍｕｓｈｒｏｏｍ）（学名：Ｐｌｅｕｒｏｔｕｓ ｏｓｔｒｅａｔｕｓ）、シイタケ（学名：Ｌｅｎｔｉｎｕｌａ ｅｄｏｄｅｓ）、マイタケ（学名：Ｇｒｉｆｏｌａ ｆｒｏｎｄｏｓａ）、レイシ（学名：Ｇａｎｏｄｅｒｍａ ｌｕｃｉｄｕｍ）、ヤマブシタケ（学名：Ｈｅｒｉｃｉｕｍ ｅｒｉｎａｃｅｕｓ）、ヤナギマツタケ（学名：Ａｇｒｏｃｙｂｅ ａｅｇｅｒｉｔａ）、アンズタケ（学名：Ｃａｎｔｈａｒｅｌｌｕｓ ｃｉｂａｒｉｕｓ）、ポルチーニ（学名：Ｂｏｌｅｔｕｓ ｅｄｕｌｉｓ）、アミガサダケ（学名：Ｍｏｒｃｈｅｌｌａ ｅｓｃｕｌｅｎｔａ）等のキノコにも含まれる。天然物からＬ－エルゴチオネインを得る場合は、タモギタケから抽出等することが好ましい。エルゴチオネイン又はその塩は、微生物発酵で製造することもできる。エルゴチオネイン又はその塩は、単離されたものであってもよい。
Ergothioneine or its salt is not limited in any way by its form or manufacturing method. Ergothioneine or a salt thereof may be a chemically synthesized product or may be extracted and purified from a natural product. L-ergothioneine is abundantly contained in Golden/Yellow Oyster Mushroom (scientific name: Pleurotus cornucopiae var. citrinopileatus), which is a mushroom of the Pleurotus family and Pleurotus genus. L-ergothioneine is extracted from Agaricus bisporus (scientific name: Agaricus bisporus), Gray Oyster Mushroom (scientific name: Pleurotus ostreatus), such as white button mushrooms, crimini mushrooms, and Portabella mushrooms. , shiitake (scientific name: Lentinula edodes), maitake (scientific name: Grifola frondosa), Reishi (scientific name: Ganoderma lucidum), Hericium erinaceus (scientific name: Hericium erinaceus), Willow matsutake (scientific name: Agrocybe aegerita), Chanterelle (scientific name: Ca) ntharellus cibarius), boletus (scientific name: Boletus edulis), morel mushroom ( It is also included in mushrooms such as Morchella esculenta (scientific name: Morchella esculenta). When L-ergothioneine is obtained from a natural product, it is preferably extracted from Tamogitake mushrooms. Ergothioneine or its salt can also be produced by microbial fermentation. Ergothioneine or a salt thereof may be isolated.
グルコサミン（２－アミノ－２－デオキシ－Ｄ－グルコース）は、グルコースの２位の水酸基がアミノ基に置換したアミノ糖であり、動物体内では、軟骨や結合組織などにムコ多糖の構成成分として広く分布している。
グルコサミンには、塩味、舌に残る甘味、えぐみを伴う特有の異味がある。
本発明の組成物は、グルコサミン類化合物を含むことにより、エルゴチオネイン又はその塩に由来する苦味が低減されている。
グルコサミン類化合物と、エルゴチオネイン又はその塩とを組み合わせることにより、グルコサミン類化合物に由来する塩味、舌に残る甘味、えぐみを伴う特有の異味を抑制することもできる。
このため、エルゴチオネイン又はその塩及びグルコサミン類化合物の継続的な摂取が容易となる。 Glucosamine (2-amino-2-deoxy-D-glucose) is an amino sugar in which the hydroxyl group at the 2-position of glucose is replaced with an amino group, and in the animal body, it is widely used as a component of mucopolysaccharide in cartilage and connective tissue. It is distributed.
Glucosamine has a unique off-taste, with a salty taste, a sweet taste that lingers on the tongue, and an astringent taste.
By containing the glucosamine compound, the composition of the present invention has reduced bitterness derived from ergothioneine or a salt thereof.
By combining a glucosamine compound and ergothioneine or a salt thereof, it is also possible to suppress the salty taste derived from the glucosamine compound, the sweet taste that remains on the tongue, and the characteristic off-taste associated with astringency.
Therefore, continuous intake of ergothioneine or its salt and glucosamine compounds becomes easy.
グルコサミンには、塩味、舌に残る甘味、えぐみを伴う特有の異味がある。
本発明の組成物は、グルコサミン類化合物を含むことにより、エルゴチオネイン又はその塩に由来する苦味が低減されている。
グルコサミン類化合物と、エルゴチオネイン又はその塩とを組み合わせることにより、グルコサミン類化合物に由来する塩味、舌に残る甘味、えぐみを伴う特有の異味を抑制することもできる。
このため、エルゴチオネイン又はその塩及びグルコサミン類化合物の継続的な摂取が容易となる。 Glucosamine (2-amino-2-deoxy-D-glucose) is an amino sugar in which the hydroxyl group at the 2-position of glucose is replaced with an amino group, and in the animal body, it is widely used as a component of mucopolysaccharide in cartilage and connective tissue. It is distributed.
Glucosamine has a unique off-taste, with a salty taste, a sweet taste that lingers on the tongue, and an astringent taste.
By containing the glucosamine compound, the composition of the present invention has reduced bitterness derived from ergothioneine or a salt thereof.
By combining a glucosamine compound and ergothioneine or a salt thereof, it is also possible to suppress the salty taste derived from the glucosamine compound, the sweet taste that remains on the tongue, and the characteristic off-taste associated with astringency.
Therefore, continuous intake of ergothioneine or its salt and glucosamine compounds becomes easy.
本発明において、グルコサミン類化合物とは、グルコサミン、その誘導体及びそれらの塩を含む化合物の総称である。
In the present invention, the glucosamine compound is a general term for compounds including glucosamine, derivatives thereof, and salts thereof.
グルコサミン誘導体としては、特に制限されないが、グルコサミンの水酸基がエステル化、エーテル化した化合物、アミノ基がアシル化した化合物等が挙げられる。
グルコサミン誘導体として、好ましくは、グルコサミンの少なくとも１つの水酸基の水素原子及び／又はアミノ基の水素原子が、炭素数１～１０のアシル基及び／又はアルキル基に置換された化合物である。より好ましくは、グルコサミンのアミノ基の水素原子が炭素数１～１０のアシル基又はアルキル基に置換された化合物である。
上記アシル基及び／又はアルキル基の炭素数として好ましくは１～８であり、より好ましくは１～５であり、更に好ましくは１～３であり、特に好ましくは２である。
アシル基として具体的には、ホルミル基、アセチル基、プロピオニル基、ベンゾイル基等が挙げられる。
グルコサミン誘導体として更に好ましくはＮ－アセチルグルコサミン、Ｎ－メチル－Ｌ－グルコサミンであり、特に好ましくはＮ－アセチルグルコサミンである。 Examples of glucosamine derivatives include, but are not particularly limited to, compounds in which the hydroxyl group of glucosamine is esterified or etherified, compounds in which the amino group is acylated, and the like.
The glucosamine derivative is preferably a compound in which at least one hydrogen atom of a hydroxyl group and/or a hydrogen atom of an amino group of glucosamine is substituted with an acyl group and/or an alkyl group having 1 to 10 carbon atoms. More preferred is a compound in which the hydrogen atom of the amino group of glucosamine is substituted with an acyl group or alkyl group having 1 to 10 carbon atoms.
The number of carbon atoms in the acyl group and/or alkyl group is preferably 1 to 8, more preferably 1 to 5, still more preferably 1 to 3, and particularly preferably 2.
Specific examples of the acyl group include formyl group, acetyl group, propionyl group, and benzoyl group.
More preferred glucosamine derivatives are N-acetylglucosamine and N-methyl-L-glucosamine, and particularly preferred is N-acetylglucosamine.
グルコサミン誘導体として、好ましくは、グルコサミンの少なくとも１つの水酸基の水素原子及び／又はアミノ基の水素原子が、炭素数１～１０のアシル基及び／又はアルキル基に置換された化合物である。より好ましくは、グルコサミンのアミノ基の水素原子が炭素数１～１０のアシル基又はアルキル基に置換された化合物である。
上記アシル基及び／又はアルキル基の炭素数として好ましくは１～８であり、より好ましくは１～５であり、更に好ましくは１～３であり、特に好ましくは２である。
アシル基として具体的には、ホルミル基、アセチル基、プロピオニル基、ベンゾイル基等が挙げられる。
グルコサミン誘導体として更に好ましくはＮ－アセチルグルコサミン、Ｎ－メチル－Ｌ－グルコサミンであり、特に好ましくはＮ－アセチルグルコサミンである。 Examples of glucosamine derivatives include, but are not particularly limited to, compounds in which the hydroxyl group of glucosamine is esterified or etherified, compounds in which the amino group is acylated, and the like.
The glucosamine derivative is preferably a compound in which at least one hydrogen atom of a hydroxyl group and/or a hydrogen atom of an amino group of glucosamine is substituted with an acyl group and/or an alkyl group having 1 to 10 carbon atoms. More preferred is a compound in which the hydrogen atom of the amino group of glucosamine is substituted with an acyl group or alkyl group having 1 to 10 carbon atoms.
The number of carbon atoms in the acyl group and/or alkyl group is preferably 1 to 8, more preferably 1 to 5, still more preferably 1 to 3, and particularly preferably 2.
Specific examples of the acyl group include formyl group, acetyl group, propionyl group, and benzoyl group.
More preferred glucosamine derivatives are N-acetylglucosamine and N-methyl-L-glucosamine, and particularly preferred is N-acetylglucosamine.
グルコサミンやその誘導体の塩としては、薬理学的に許容される塩又は飲食品に許容される塩であれば特に限定されないが、例えば、塩酸塩、硫酸塩、硝酸塩、リン酸塩等の無機酸塩；酢酸塩、クエン酸塩、マレイン酸塩、リンゴ酸塩、シュウ酸塩、乳酸塩、コハク酸塩、フマル酸塩、プロピオン酸塩等の有機酸塩等が挙げられる。好ましくは無機酸塩であり、より好ましくは塩酸塩である。
Salts of glucosamine and its derivatives are not particularly limited as long as they are pharmacologically acceptable salts or salts that are acceptable for food and beverages, but include inorganic acids such as hydrochlorides, sulfates, nitrates, and phosphates. Salts; organic acid salts such as acetate, citrate, maleate, malate, oxalate, lactate, succinate, fumarate, propionate, and the like. Preferably it is an inorganic acid salt, more preferably a hydrochloride.
本発明に用いられるグルコサミン類化合物は、その形態や製造方法等によって、何ら制限されるものではなく、市販品を使用してもよく、天然物から抽出及び精製したものを使用してもよい。例えば、グルコサミンの場合は、カニ、エビ、オキアミ等の甲殻類やイカの軟骨等に含まれるキチンを酸又は酵素により加水分解し、分離及び精製することによって得ることができる。
The glucosamine compound used in the present invention is not limited in any way by its form or manufacturing method, and commercially available products may be used, or those extracted and purified from natural products may be used. For example, in the case of glucosamine, it can be obtained by hydrolyzing chitin contained in crustaceans such as crabs, shrimps, and krill, and cartilage of squid using acids or enzymes, followed by separation and purification.
本発明の組成物において、成分（Ａ）（エルゴチオネイン換算）に対する、成分（Ｂ）（グルコサミン換算）の重量比（グルコサミン換算の（Ｂ）／エルゴチオネイン換算の（Ａ））は、０．２～１５０である。
エルゴチオネイン又はその塩には、舌を刺すような苦味がある。また、グルコサミン類化合物にも特有の異味がある。成分（Ａ）及び（Ｂ）を含む組成物において、成分（Ａ）（エルゴチオネイン換算）に対する、成分（Ｂ）（グルコサミン換算）の重量比（（Ｂ）／（Ａ））が上記範囲であると、成分（Ａ）に由来する苦味を抑制することができるとともに、成分（Ｂ）に由来する異味も抑制することができる。このため、エルゴチオネイン又はその塩とグルコサミン類化合物との継続的な摂取が容易となる。
上記重量比（（Ｂ）／（Ａ））として好ましくは、０．４～１３０であり、より好ましくは０．５～１２０であり、更に好ましくは１～１００であり、特に好ましくは５～８０であり、最も好ましくは１０～５０である。 In the composition of the present invention, the weight ratio of component (B) (in terms of glucosamine) to component (A) (in terms of ergothioneine) ((B) in terms of glucosamine/(A) in terms of ergothioneine) is 0.2 to 150. It is.
Ergothioneine or its salts have a bitter taste that stings the tongue. Glucosamine compounds also have a unique off-taste. In a composition containing components (A) and (B), the weight ratio ((B)/(A)) of component (B) (in terms of glucosamine) to component (A) (in terms of ergothioneine) is within the above range. , it is possible to suppress the bitter taste derived from component (A), and also to suppress the off-taste derived from component (B). Therefore, continuous intake of ergothioneine or its salt and glucosamine compound becomes easy.
The weight ratio ((B)/(A)) is preferably 0.4 to 130, more preferably 0.5 to 120, even more preferably 1 to 100, particularly preferably 5 to 80. and most preferably 10-50.
エルゴチオネイン又はその塩には、舌を刺すような苦味がある。また、グルコサミン類化合物にも特有の異味がある。成分（Ａ）及び（Ｂ）を含む組成物において、成分（Ａ）（エルゴチオネイン換算）に対する、成分（Ｂ）（グルコサミン換算）の重量比（（Ｂ）／（Ａ））が上記範囲であると、成分（Ａ）に由来する苦味を抑制することができるとともに、成分（Ｂ）に由来する異味も抑制することができる。このため、エルゴチオネイン又はその塩とグルコサミン類化合物との継続的な摂取が容易となる。
上記重量比（（Ｂ）／（Ａ））として好ましくは、０．４～１３０であり、より好ましくは０．５～１２０であり、更に好ましくは１～１００であり、特に好ましくは５～８０であり、最も好ましくは１０～５０である。 In the composition of the present invention, the weight ratio of component (B) (in terms of glucosamine) to component (A) (in terms of ergothioneine) ((B) in terms of glucosamine/(A) in terms of ergothioneine) is 0.2 to 150. It is.
Ergothioneine or its salts have a bitter taste that stings the tongue. Glucosamine compounds also have a unique off-taste. In a composition containing components (A) and (B), the weight ratio ((B)/(A)) of component (B) (in terms of glucosamine) to component (A) (in terms of ergothioneine) is within the above range. , it is possible to suppress the bitter taste derived from component (A), and also to suppress the off-taste derived from component (B). Therefore, continuous intake of ergothioneine or its salt and glucosamine compound becomes easy.
The weight ratio ((B)/(A)) is preferably 0.4 to 130, more preferably 0.5 to 120, even more preferably 1 to 100, particularly preferably 5 to 80. and most preferably 10-50.
本発明の組成物に含まれるエルゴチオネイン又はその塩の含有量は特に限定されず、その形態等に応じて設定することができる。
本発明の組成物中のエルゴチオネイン又はその塩の含有量は、エルゴチオネイン換算で、例えば、該組成物中に０．１重量％以上が好ましく、０．５重量％以上がより好ましく、０．６重量％以上が更に好ましく、０．８重量％以上が更により好ましく、１重量％以上が特に好ましく、また、５０重量％以下が好ましく、４０重量％以下がより好ましく、３０重量％以下が更に好ましく、２０重量％以下が更により好ましく、１０重量％以下が特に好ましい。一態様において、エルゴチオネイン又はその塩の含有量は、エルゴチオネイン換算で、本発明の組成物中に０．１～５０重量％が好ましく、０．５～４０重量％がより好ましく、０．６～３０重量％が更に好ましく、０．８～２０重量％が更により好ましく、１～１０重量％が特に好ましい。本発明の組成物がエルゴチオネイン又はその塩として２種以上の化合物を含有する場合、エルゴチオネイン又はその塩の含有量は、それらの合計含有量である。エルゴチオネインの含有量は、高速液体クロマトグラフィー（ＨＰＬＣ）法により測定することができる。
エルゴチオネイン又はその塩のエルゴチオネイン換算の量又はこれに類する表現は、エルゴチオネインの場合は、その量を意味する。エルゴチオネインの塩の場合は、当該塩のモル数に、エルゴチオネインの分子量を乗じて得られる値を意味する。 The content of ergothioneine or its salt contained in the composition of the present invention is not particularly limited, and can be set depending on its form and the like.
The content of ergothioneine or its salt in the composition of the present invention is preferably 0.1% by weight or more, more preferably 0.5% by weight or more, and 0.6% by weight in terms of ergothioneine. % or more, still more preferably 0.8% by weight or more, particularly preferably 1% by weight or more, and preferably 50% by weight or less, more preferably 40% by weight or less, even more preferably 30% by weight or less, It is even more preferably 20% by weight or less, particularly preferably 10% by weight or less. In one embodiment, the content of ergothioneine or a salt thereof in the composition of the present invention is preferably 0.1 to 50% by weight, more preferably 0.5 to 40% by weight, and 0.6 to 30% by weight in terms of ergothioneine. % by weight is more preferred, 0.8 to 20% by weight is even more preferred, and 1 to 10% by weight is particularly preferred. When the composition of the present invention contains two or more compounds as ergothioneine or its salt, the content of ergothioneine or its salt is the total content thereof. The content of ergothioneine can be measured by high performance liquid chromatography (HPLC).
The amount of ergothioneine or a salt thereof in terms of ergothioneine or a similar expression means, in the case of ergothioneine, the amount. In the case of a salt of ergothioneine, it means the value obtained by multiplying the number of moles of the salt by the molecular weight of ergothioneine.
本発明の組成物中のエルゴチオネイン又はその塩の含有量は、エルゴチオネイン換算で、例えば、該組成物中に０．１重量％以上が好ましく、０．５重量％以上がより好ましく、０．６重量％以上が更に好ましく、０．８重量％以上が更により好ましく、１重量％以上が特に好ましく、また、５０重量％以下が好ましく、４０重量％以下がより好ましく、３０重量％以下が更に好ましく、２０重量％以下が更により好ましく、１０重量％以下が特に好ましい。一態様において、エルゴチオネイン又はその塩の含有量は、エルゴチオネイン換算で、本発明の組成物中に０．１～５０重量％が好ましく、０．５～４０重量％がより好ましく、０．６～３０重量％が更に好ましく、０．８～２０重量％が更により好ましく、１～１０重量％が特に好ましい。本発明の組成物がエルゴチオネイン又はその塩として２種以上の化合物を含有する場合、エルゴチオネイン又はその塩の含有量は、それらの合計含有量である。エルゴチオネインの含有量は、高速液体クロマトグラフィー（ＨＰＬＣ）法により測定することができる。
エルゴチオネイン又はその塩のエルゴチオネイン換算の量又はこれに類する表現は、エルゴチオネインの場合は、その量を意味する。エルゴチオネインの塩の場合は、当該塩のモル数に、エルゴチオネインの分子量を乗じて得られる値を意味する。 The content of ergothioneine or its salt contained in the composition of the present invention is not particularly limited, and can be set depending on its form and the like.
The content of ergothioneine or its salt in the composition of the present invention is preferably 0.1% by weight or more, more preferably 0.5% by weight or more, and 0.6% by weight in terms of ergothioneine. % or more, still more preferably 0.8% by weight or more, particularly preferably 1% by weight or more, and preferably 50% by weight or less, more preferably 40% by weight or less, even more preferably 30% by weight or less, It is even more preferably 20% by weight or less, particularly preferably 10% by weight or less. In one embodiment, the content of ergothioneine or a salt thereof in the composition of the present invention is preferably 0.1 to 50% by weight, more preferably 0.5 to 40% by weight, and 0.6 to 30% by weight in terms of ergothioneine. % by weight is more preferred, 0.8 to 20% by weight is even more preferred, and 1 to 10% by weight is particularly preferred. When the composition of the present invention contains two or more compounds as ergothioneine or its salt, the content of ergothioneine or its salt is the total content thereof. The content of ergothioneine can be measured by high performance liquid chromatography (HPLC).
The amount of ergothioneine or a salt thereof in terms of ergothioneine or a similar expression means, in the case of ergothioneine, the amount. In the case of a salt of ergothioneine, it means the value obtained by multiplying the number of moles of the salt by the molecular weight of ergothioneine.
本発明の組成物に含まれるグルコサミン類化合物の含有量は特に限定されず、その形態等に応じて設定することができる。本発明の組成物中のグルコサミン類化合物の含有量は、グルコサミン換算で、例えば、該組成物中に０．０２重量％以上が好ましく、０．１重量％以上がより好ましく、１重量％以上が更に好ましく、５重量％以上が更により好ましく、１０重量％以上が一層好ましく、２０重量％以上が更に一層好ましく、３０重量％以上が特に好ましく、４０重量％以上が特に一層好ましく、また、９９重量％以下が好ましく、９５重量％以下がより好ましく、９０重量％以下が更に好ましく、８０重量％以下が更により好ましく、７０重量％以下が更に一層好ましく、６０重量％以下が特に好ましい。一態様において、グルコサミン類化合物の含有量は、グルコサミン換算で、本発明の組成物中に、０．０２～９９重量％が好ましく、０．１～９９重量％がより好ましく、１～９９重量％が更に好ましく、５～９５重量％が更により好ましく、１０～９０重量％が一層好ましく、２０～８０重量％が更に一層好ましく、３０～７０重量％が特に好ましく、４０～６０重量％が特に一層好ましい。上記含有量は、グルコサミン類化合物として２種以上の化合物を含有する場合は、それらの合計含有量である。グルコサミン類化合物の含有量は、ＨＰＬＣ法により測定することができる。
グルコサミン類化合物のグルコサミン換算の量又はこれに類する表現は、グルコサミンの場合は、その量を意味する。グルコサミン以外の化合物の場合は、当該化合物のモル数に、グルコサミンの分子量を乗じて得られる値を意味する。 The content of glucosamine compounds contained in the composition of the present invention is not particularly limited, and can be set depending on its form and the like. The content of glucosamine compounds in the composition of the present invention is, in terms of glucosamine, preferably 0.02% by weight or more, more preferably 0.1% by weight or more, and 1% by weight or more in the composition. More preferably, 5% by weight or more, even more preferably 10% by weight or more, even more preferably 20% by weight or more, particularly preferably 30% by weight or more, particularly still more preferably 40% by weight or more, and 99% by weight or more. % or less, more preferably 95% by weight or less, even more preferably 90% by weight or less, even more preferably 80% by weight or less, even more preferably 70% by weight or less, particularly preferably 60% by weight or less. In one embodiment, the content of the glucosamine compound in the composition of the present invention is preferably 0.02 to 99% by weight, more preferably 0.1 to 99% by weight, and 1 to 99% by weight in terms of glucosamine. is even more preferred, 5 to 95% by weight is even more preferred, 10 to 90% by weight is even more preferred, 20 to 80% by weight is even more preferred, 30 to 70% by weight is particularly preferred, and 40 to 60% by weight is even more particularly preferred. preferable. When two or more kinds of compounds are contained as glucosamine compounds, the above content is the total content thereof. The content of glucosamine compounds can be measured by HPLC method.
The amount of a glucosamine compound in terms of glucosamine or a similar expression means the amount in the case of glucosamine. In the case of a compound other than glucosamine, it means the value obtained by multiplying the number of moles of the compound by the molecular weight of glucosamine.
グルコサミン類化合物のグルコサミン換算の量又はこれに類する表現は、グルコサミンの場合は、その量を意味する。グルコサミン以外の化合物の場合は、当該化合物のモル数に、グルコサミンの分子量を乗じて得られる値を意味する。 The content of glucosamine compounds contained in the composition of the present invention is not particularly limited, and can be set depending on its form and the like. The content of glucosamine compounds in the composition of the present invention is, in terms of glucosamine, preferably 0.02% by weight or more, more preferably 0.1% by weight or more, and 1% by weight or more in the composition. More preferably, 5% by weight or more, even more preferably 10% by weight or more, even more preferably 20% by weight or more, particularly preferably 30% by weight or more, particularly still more preferably 40% by weight or more, and 99% by weight or more. % or less, more preferably 95% by weight or less, even more preferably 90% by weight or less, even more preferably 80% by weight or less, even more preferably 70% by weight or less, particularly preferably 60% by weight or less. In one embodiment, the content of the glucosamine compound in the composition of the present invention is preferably 0.02 to 99% by weight, more preferably 0.1 to 99% by weight, and 1 to 99% by weight in terms of glucosamine. is even more preferred, 5 to 95% by weight is even more preferred, 10 to 90% by weight is even more preferred, 20 to 80% by weight is even more preferred, 30 to 70% by weight is particularly preferred, and 40 to 60% by weight is even more particularly preferred. preferable. When two or more kinds of compounds are contained as glucosamine compounds, the above content is the total content thereof. The content of glucosamine compounds can be measured by HPLC method.
The amount of a glucosamine compound in terms of glucosamine or a similar expression means the amount in the case of glucosamine. In the case of a compound other than glucosamine, it means the value obtained by multiplying the number of moles of the compound by the molecular weight of glucosamine.
本発明の組成物は、エルゴチオネイン又はその塩の含有量が、成人の１日摂取量当たり、エルゴチオネイン換算で１～１００ｍｇであることが好ましく、２～５０ｍｇであることがより好ましく、５～２５ｍｇであることが更に好ましく、５～２０ｍｇであることが特に好ましい。
本発明の組成物は、グルコサミン類化合物の含有量が、成人の１日摂取量当たり、グルコサミン換算で１０～５０００ｍｇであることが好ましく、２０～３０００ｍｇであることがより好ましく、５０～２０００ｍｇであることが更に好ましい。 In the composition of the present invention, the content of ergothioneine or its salt is preferably 1 to 100 mg, more preferably 2 to 50 mg, and more preferably 5 to 25 mg in terms of ergothioneine per daily intake for adults. More preferably, the amount is 5 to 20 mg, particularly preferably 5 to 20 mg.
In the composition of the present invention, the content of glucosamine compounds is preferably 10 to 5000 mg, more preferably 20 to 3000 mg, and more preferably 50 to 2000 mg in terms of glucosamine per daily intake for adults. More preferably.
本発明の組成物は、グルコサミン類化合物の含有量が、成人の１日摂取量当たり、グルコサミン換算で１０～５０００ｍｇであることが好ましく、２０～３０００ｍｇであることがより好ましく、５０～２０００ｍｇであることが更に好ましい。 In the composition of the present invention, the content of ergothioneine or its salt is preferably 1 to 100 mg, more preferably 2 to 50 mg, and more preferably 5 to 25 mg in terms of ergothioneine per daily intake for adults. More preferably, the amount is 5 to 20 mg, particularly preferably 5 to 20 mg.
In the composition of the present invention, the content of glucosamine compounds is preferably 10 to 5000 mg, more preferably 20 to 3000 mg, and more preferably 50 to 2000 mg in terms of glucosamine per daily intake for adults. More preferably.
エルゴチオネイン又はその塩及びグルコサミン類化合物は、天然物や飲食品に含まれ、食経験がある化合物である。このため安全性の観点から、エルゴチオネイン又はその塩及びグルコサミン類化合物は、例えば毎日摂取することにも問題が少ないと考えられる。本発明によれば、安全性が高く、エルゴチオネイン又はその塩に由来する苦味及びグルコサミン類化合物に由来する異味が低減されて摂取しやすい組成物を提供することができる。
Ergothioneine or its salts and glucosamine compounds are compounds that are contained in natural products and food and drink products and have been eaten. Therefore, from the viewpoint of safety, ergothioneine or its salts and glucosamine compounds are considered to pose few problems when ingested, for example, every day. According to the present invention, it is possible to provide a composition that is highly safe, has reduced bitterness derived from ergothioneine or its salt, and reduced off-taste derived from glucosamine compounds, and is easy to ingest.
エルゴチオネイン又はその塩は、上述のとおり、多様な生理活性や健康機能を発揮することが知られており、例えば、抗酸化作用、脳機能改善効果、抗老化作用、眼疾患改善効果、美白効果、紫外線吸収効果、メラニン産生抑制効果、活性酸素種の消去作用、エラスターゼ活性阻害効果、シワ形成抑制効果、肌のたるみ抑制効果、オートファジー促進効果等が知られている。
このため、本発明の組成物は、抗酸化用、脳機能改善用、抗老化用、眼疾患用、美白用、紫外線吸収用、メラニン産生抑制用、活性酸素種の消去用、エラスターゼ活性阻害用、シワ形成抑制用、肌のたるみ抑制用、オートファジー促進用等に好適に用いることができる。 As mentioned above, ergothioneine or its salts are known to exhibit various physiological activities and health functions, such as antioxidant effects, brain function improvement effects, anti-aging effects, eye disease improvement effects, whitening effects, It is known for its ultraviolet absorbing effect, melanin production suppressing effect, active oxygen species scavenging effect, elastase activity inhibiting effect, wrinkle formation suppressing effect, skin sagging suppressing effect, autophagy promoting effect, etc.
Therefore, the composition of the present invention can be used for antioxidant purposes, for improving brain function, for anti-aging, for eye diseases, for whitening, for absorbing ultraviolet rays, for suppressing melanin production, for eliminating reactive oxygen species, and for inhibiting elastase activity. It can be suitably used for suppressing wrinkle formation, suppressing skin sagging, promoting autophagy, etc.
このため、本発明の組成物は、抗酸化用、脳機能改善用、抗老化用、眼疾患用、美白用、紫外線吸収用、メラニン産生抑制用、活性酸素種の消去用、エラスターゼ活性阻害用、シワ形成抑制用、肌のたるみ抑制用、オートファジー促進用等に好適に用いることができる。 As mentioned above, ergothioneine or its salts are known to exhibit various physiological activities and health functions, such as antioxidant effects, brain function improvement effects, anti-aging effects, eye disease improvement effects, whitening effects, It is known for its ultraviolet absorbing effect, melanin production suppressing effect, active oxygen species scavenging effect, elastase activity inhibiting effect, wrinkle formation suppressing effect, skin sagging suppressing effect, autophagy promoting effect, etc.
Therefore, the composition of the present invention can be used for antioxidant purposes, for improving brain function, for anti-aging, for eye diseases, for whitening, for absorbing ultraviolet rays, for suppressing melanin production, for eliminating reactive oxygen species, and for inhibiting elastase activity. It can be suitably used for suppressing wrinkle formation, suppressing skin sagging, promoting autophagy, etc.
グルコサミン類化合物については、変形性膝関節症や変形性股関節症等の痛みの改善等の健康機能を発揮することが知られている。本発明の組成物はグルコサミン類化合物を含有することから、これらにより発揮される上記の効果を得るために使用することもできる。
Glucosamine compounds are known to exert health functions such as improving pain caused by knee osteoarthritis and hip osteoarthritis. Since the composition of the present invention contains glucosamine compounds, it can also be used to obtain the above effects exerted by these compounds.
本発明の組成物は、治療的用途（医療用途）又は非治療的用途（非医療用途）のいずれにも適用することができる。非治療的とは、医療行為、すなわち人間の手術、治療又は診断を含まない概念である。
本発明の組成物は、飲食品、医薬品、医薬部外品、飼料等の形態とすることができる。本発明の組成物は、飲食品、医薬品、医薬部外品、飼料等に配合して使用される素材又は製剤等であってもよい。 The compositions of the invention can be applied for either therapeutic (medical) or non-therapeutic (non-medical) uses. Non-therapeutic is a concept that does not include medical procedures, ie, surgery, treatment, or diagnosis of humans.
The composition of the present invention can be in the form of a food or drink, a drug, a quasi-drug, a feed, or the like. The composition of the present invention may be a material or a preparation used by being mixed into foods and drinks, pharmaceuticals, quasi-drugs, feeds, and the like.
本発明の組成物は、飲食品、医薬品、医薬部外品、飼料等の形態とすることができる。本発明の組成物は、飲食品、医薬品、医薬部外品、飼料等に配合して使用される素材又は製剤等であってもよい。 The compositions of the invention can be applied for either therapeutic (medical) or non-therapeutic (non-medical) uses. Non-therapeutic is a concept that does not include medical procedures, ie, surgery, treatment, or diagnosis of humans.
The composition of the present invention can be in the form of a food or drink, a drug, a quasi-drug, a feed, or the like. The composition of the present invention may be a material or a preparation used by being mixed into foods and drinks, pharmaceuticals, quasi-drugs, feeds, and the like.
本発明の組成物は、経口用の組成物であり、経口組成物として具体的には、飲食品、経口用の医薬品、医薬部外品、飼料等が挙げられ、好ましくは飲食品又は経口用医薬品であり、より好ましくは飲食品である。
The composition of the present invention is a composition for oral use, and specific examples of the oral composition include food and drink products, oral drugs, quasi-drugs, feeds, etc., and preferably food and drink products or oral compositions. It is a medicine, and more preferably a food or drink.
本発明の組成物は、本発明の効果を損なわない限り、エルゴチオネイン又はその塩及びグルコサミン類化合物に加えて、任意の添加剤、任意の成分を含有することができる。これらの添加剤及び成分は、組成物の形態等に応じて選択することができ、一般的に飲食品、医薬品、医薬部外品、飼料等の経口組成物に使用可能なものが使用できる。本発明の組成物を、飲食品、医薬品、医薬部外品、飼料等とする場合、その製造方法は特に限定されず、一般的な方法により製造することができる。一態様において、本発明の組成物は、エルゴチオネイン又はその塩及びグルコサミン類化合物からなるものであってもよい。
本発明の経口組成物の形態は特に限定されず、固体状（粉末状、顆粒状、タブレット状等）、液状、ペースト状等であってよい。 The composition of the present invention may contain arbitrary additives and arbitrary components in addition to ergothioneine or a salt thereof and a glucosamine compound, as long as the effects of the present invention are not impaired. These additives and components can be selected depending on the form of the composition, etc., and those that can be generally used in oral compositions such as foods and drinks, pharmaceuticals, quasi-drugs, and feeds can be used. When the composition of the present invention is used as a food or drink, a drug, a quasi-drug, a feed, etc., the manufacturing method thereof is not particularly limited, and it can be manufactured by a general method. In one embodiment, the composition of the present invention may consist of ergothioneine or a salt thereof and a glucosamine compound.
The form of the oral composition of the present invention is not particularly limited, and may be solid (powder, granule, tablet, etc.), liquid, paste, or the like.
本発明の経口組成物の形態は特に限定されず、固体状（粉末状、顆粒状、タブレット状等）、液状、ペースト状等であってよい。 The composition of the present invention may contain arbitrary additives and arbitrary components in addition to ergothioneine or a salt thereof and a glucosamine compound, as long as the effects of the present invention are not impaired. These additives and components can be selected depending on the form of the composition, etc., and those that can be generally used in oral compositions such as foods and drinks, pharmaceuticals, quasi-drugs, and feeds can be used. When the composition of the present invention is used as a food or drink, a drug, a quasi-drug, a feed, etc., the manufacturing method thereof is not particularly limited, and it can be manufactured by a general method. In one embodiment, the composition of the present invention may consist of ergothioneine or a salt thereof and a glucosamine compound.
The form of the oral composition of the present invention is not particularly limited, and may be solid (powder, granule, tablet, etc.), liquid, paste, or the like.
例えば本発明の組成物を飲食品とする場合、エルゴチオネイン又はその塩及びグルコサミン類化合物に、飲食品に使用可能な成分（例えば、食品素材、必要に応じて使用される食品添加物等）を配合して、種々の飲食品とすることができる。飲食品は特に限定されず、例えば、一般的な飲食品、健康食品、健康補助食品、健康飲料、機能性表示食品、特定保健用食品、病者用飲食品等が挙げられる。上記健康食品、健康補助食品、機能性表示食品、特定保健用食品等は、例えば、細粒剤、錠剤、顆粒剤、散剤、カプセル剤、チュアブル剤、ドライシロップ剤、シロップ剤、液剤、飲料、ドリンク剤、流動食等の各種製剤形態として使用することができる。
For example, when the composition of the present invention is used as a food or drink, ingredients that can be used in food or drink (e.g., food materials, food additives used as necessary, etc.) are added to ergothioneine or its salt and glucosamine compounds. It can be made into various food and drink products. Foods and drinks are not particularly limited, and include, for example, general foods and drinks, health foods, health supplements, health drinks, foods with functional claims, foods for specified health uses, foods and drinks for patients, and the like. The above health foods, health supplements, foods with functional claims, foods for specified health uses, etc. include fine granules, tablets, granules, powders, capsules, chewables, dry syrups, syrups, liquids, beverages, and drinks. It can be used in various formulations such as tablets and liquid foods.
本発明の組成物を医薬品又は医薬部外品とする場合、例えば、エルゴチオネイン又はその塩及びグルコサミン類化合物に、薬理学的に許容される担体、必要に応じて添加される添加剤等を配合して、各種剤形の医薬品又は医薬部外品とすることができる。そのような担体、添加剤等は、医薬品又は医薬部外品に使用可能な、薬理学的に許容されるものであればよく、例えば、賦形剤、結合剤、崩壊剤、滑沢剤、抗酸化剤、着色剤等の１又は２以上が挙げられる。医薬品又は医薬部外品の経口投与のための剤形としては、液剤、錠剤、散剤、細粒剤、顆粒剤、糖衣錠、カプセル剤、懸濁液、乳剤、チュアブル剤等が挙げられる。
When the composition of the present invention is used as a drug or quasi-drug, for example, ergothioneine or a salt thereof and a glucosamine compound are mixed with a pharmacologically acceptable carrier, additives added as necessary, etc. It can be used as pharmaceuticals or quasi-drugs in various dosage forms. Such carriers, additives, etc. may be pharmacologically acceptable ones that can be used in pharmaceuticals or quasi-drugs, such as excipients, binders, disintegrants, lubricants, One or more of antioxidants, colorants, etc. may be used. Dosage forms for oral administration of pharmaceuticals or quasi-drugs include liquids, tablets, powders, fine granules, granules, sugar-coated tablets, capsules, suspensions, emulsions, chewables, and the like.
本発明の組成物を飼料とする場合には、エルゴチオネイン又はその塩及びグルコサミン類化合物を飼料に配合すればよい。飼料には飼料添加剤も含まれる。飼料としては、例えば、牛、豚、鶏、羊、馬等に用いる家畜用飼料；ウサギ、ラット、マウス等に用いる小動物用飼料；犬、猫、小鳥等に用いるペットフードなどが挙げられる。
When the composition of the present invention is used as feed, ergothioneine or a salt thereof and a glucosamine compound may be added to the feed. Feed also includes feed additives. Examples of the feed include livestock feed for cows, pigs, chickens, sheep, horses, etc.; small animal feed for rabbits, rats, mice, etc.; pet foods for dogs, cats, small birds, etc.
本発明の組成物を摂取させる又は投与する対象（投与対象ということもできる）は、特に限定されない。好ましくはヒト又は非ヒト哺乳動物であり、より好ましくはヒトである。
The subject to whom the composition of the present invention is ingested or administered (also referred to as the subject of administration) is not particularly limited. Preferably it is a human or non-human mammal, more preferably a human.
本発明は、以下の方法も包含する。
（Ａ）エルゴチオネイン又はその塩、及び、（Ｂ）グルコサミン類化合物、を含有する経口組成物において、成分（Ａ）（エルゴチオネイン換算）に対する、成分（Ｂ）（グルコサミン換算）の重量比（（Ｂ）／（Ａ））を０．２～１５０に調整する、エルゴチオネイン又はその塩に由来する苦味及びグルコサミン類化合物に由来する異味を抑制する方法。
経口組成物の調製において、成分（Ａ）（エルゴチオネイン換算）に対する、成分（Ｂ）（グルコサミン換算）の重量比（（Ｂ）／（Ａ））を上記範囲に調整することで、エルゴチオネイン又はその塩に由来する苦味及びグルコサミン類化合物に由来する異味が抑制された経口組成物を得ることができる。 The present invention also includes the following method.
In an oral composition containing (A) ergothioneine or a salt thereof, and (B) a glucosamine compound, the weight ratio of component (B) (in terms of glucosamine) to component (A) (in terms of ergothioneine) ((B) /(A)) to 0.2 to 150, a method for suppressing bitterness derived from ergothioneine or a salt thereof and off-taste derived from glucosamine compounds.
In preparing an oral composition, by adjusting the weight ratio ((B)/(A)) of component (B) (in terms of glucosamine) to component (A) (in terms of ergothioneine) to the above range, ergothioneine or a salt thereof can be obtained. It is possible to obtain an oral composition in which the bitter taste derived from glucosamine compounds and the off-taste derived from glucosamine compounds are suppressed.
（Ａ）エルゴチオネイン又はその塩、及び、（Ｂ）グルコサミン類化合物、を含有する経口組成物において、成分（Ａ）（エルゴチオネイン換算）に対する、成分（Ｂ）（グルコサミン換算）の重量比（（Ｂ）／（Ａ））を０．２～１５０に調整する、エルゴチオネイン又はその塩に由来する苦味及びグルコサミン類化合物に由来する異味を抑制する方法。
経口組成物の調製において、成分（Ａ）（エルゴチオネイン換算）に対する、成分（Ｂ）（グルコサミン換算）の重量比（（Ｂ）／（Ａ））を上記範囲に調整することで、エルゴチオネイン又はその塩に由来する苦味及びグルコサミン類化合物に由来する異味が抑制された経口組成物を得ることができる。 The present invention also includes the following method.
In an oral composition containing (A) ergothioneine or a salt thereof, and (B) a glucosamine compound, the weight ratio of component (B) (in terms of glucosamine) to component (A) (in terms of ergothioneine) ((B) /(A)) to 0.2 to 150, a method for suppressing bitterness derived from ergothioneine or a salt thereof and off-taste derived from glucosamine compounds.
In preparing an oral composition, by adjusting the weight ratio ((B)/(A)) of component (B) (in terms of glucosamine) to component (A) (in terms of ergothioneine) to the above range, ergothioneine or a salt thereof can be obtained. It is possible to obtain an oral composition in which the bitter taste derived from glucosamine compounds and the off-taste derived from glucosamine compounds are suppressed.
上記の方法により、エルゴチオネイン又はその塩に由来する苦味及びグルコサミン類化合物に由来する異味を効果的に抑制することが可能となる。エルゴチオネイン又はその塩に由来する苦味及びグルコサミン類化合物に由来する異味を抑制することによって、経口組成物の呈味を改善することができる。
上記の方法において、エルゴチオネイン又はその塩、グルコサミン類化合物及びそれらの好ましい態様は、上述した本発明の経口組成物と同じである。成分（Ａ）（エルゴチオネイン換算）に対する、成分（Ｂ）（グルコサミン換算）の重量比（（Ｂ）／（Ａ））の好ましい範囲も、本発明の経口組成物と同じである。 The above method makes it possible to effectively suppress the bitter taste derived from ergothioneine or its salt and the off-taste derived from glucosamine compounds. By suppressing the bitter taste derived from ergothioneine or its salt and the off-taste derived from glucosamine compounds, the taste of the oral composition can be improved.
In the above method, ergothioneine or a salt thereof, glucosamine compounds, and preferred embodiments thereof are the same as in the oral composition of the present invention described above. The preferred range of the weight ratio ((B)/(A)) of component (B) (in terms of glucosamine) to component (A) (in terms of ergothioneine) is also the same as in the oral composition of the present invention.
上記の方法において、エルゴチオネイン又はその塩、グルコサミン類化合物及びそれらの好ましい態様は、上述した本発明の経口組成物と同じである。成分（Ａ）（エルゴチオネイン換算）に対する、成分（Ｂ）（グルコサミン換算）の重量比（（Ｂ）／（Ａ））の好ましい範囲も、本発明の経口組成物と同じである。 The above method makes it possible to effectively suppress the bitter taste derived from ergothioneine or its salt and the off-taste derived from glucosamine compounds. By suppressing the bitter taste derived from ergothioneine or its salt and the off-taste derived from glucosamine compounds, the taste of the oral composition can be improved.
In the above method, ergothioneine or a salt thereof, glucosamine compounds, and preferred embodiments thereof are the same as in the oral composition of the present invention described above. The preferred range of the weight ratio ((B)/(A)) of component (B) (in terms of glucosamine) to component (A) (in terms of ergothioneine) is also the same as in the oral composition of the present invention.
上記の方法によって、エルゴチオネイン又はその塩に由来する苦味及びグルコサミン類化合物に由来する異味を抑制することができるが、これらの不快な風味の抑制方法として他の方法を組み合わせてもよい。
他の抑制方法としては例えば、これらの不快な風味を有する成分に甘味剤又は矯味剤を添加して製剤化する方法、該成分を糖衣で被覆して製剤化する方法、又はカプセルに封入して製剤化する方法等が挙げられる。 Although the above method can suppress the bitter taste derived from ergothioneine or its salt and the off-taste derived from glucosamine compounds, other methods may be combined to suppress these unpleasant flavors.
Other suppression methods include, for example, adding sweeteners or flavoring agents to ingredients with unpleasant flavors to formulate formulations, coating the ingredients with sugar to formulate formulations, or encapsulating the ingredients in capsules. Examples include methods for formulating formulations.
他の抑制方法としては例えば、これらの不快な風味を有する成分に甘味剤又は矯味剤を添加して製剤化する方法、該成分を糖衣で被覆して製剤化する方法、又はカプセルに封入して製剤化する方法等が挙げられる。 Although the above method can suppress the bitter taste derived from ergothioneine or its salt and the off-taste derived from glucosamine compounds, other methods may be combined to suppress these unpleasant flavors.
Other suppression methods include, for example, adding sweeteners or flavoring agents to ingredients with unpleasant flavors to formulate formulations, coating the ingredients with sugar to formulate formulations, or encapsulating the ingredients in capsules. Examples include methods for formulating formulations.
グルコサミン類化合物は、エルゴチオネイン又はその塩の苦味を抑制するために有用である。本発明は、（Ａ）エルゴチオネイン又はその塩に由来する苦味を抑制するための、（Ｂ）グルコサミン類化合物の使用、も包含する。グルコサミン類化合物の使用量は、（Ａ）エルゴチオネイン又はその塩（エルゴチオネイン換算）に対する、（Ｂ）グルコサミン類化合物（グルコサミン換算）の重量比（（Ｂ）／（Ａ））が０．２以上となる量が好ましく、上記重量比が０．２～１５０となる量がより好ましい。
Glucosamine compounds are useful for suppressing the bitter taste of ergothioneine or its salt. The present invention also includes the use of (B) a glucosamine compound to suppress the bitter taste derived from (A) ergothioneine or a salt thereof. The amount of glucosamine compounds to be used is such that the weight ratio ((B)/(A)) of (B) glucosamine compounds (in terms of glucosamine) to (A) ergothioneine or its salt (in terms of ergothioneine) is 0.2 or more. The amount is preferable, and the amount such that the above weight ratio is 0.2 to 150 is more preferable.
エルゴチオネイン又はその塩は、グルコサミン類化合物の異味を抑制するために有用である。本発明は、（Ｂ）グルコサミン類化合物由来の異味を抑制するための、（Ａ）エルゴチオネイン又はその塩の使用、も包含する。エルゴチオネイン又はその塩の使用量は、（Ａ）エルゴチオネイン又はその塩（エルゴチオネイン換算）に対する、（Ｂ）グルコサミン類化合物（グルコサミン換算）の重量比（（Ｂ）／（Ａ））が０．２以上となる量が好ましく、上記重量比が０．２～１５０となる量がより好ましい。
Ergothioneine or a salt thereof is useful for suppressing the off-taste of glucosamine compounds. The present invention also includes the use of (A) ergothioneine or a salt thereof to suppress the off-taste derived from (B) glucosamine compounds. The amount of ergothioneine or its salt to be used is such that the weight ratio ((B)/(A)) of (B) glucosamine compound (in terms of glucosamine) to (A) ergothioneine or its salt (in terms of ergothioneine) is 0.2 or more. The amount is preferably such that the above weight ratio is 0.2 to 150.
本明細書において下限値と上限値によって表されている数値範囲、即ち「下限値～上限値」は、それら下限値及び上限値を含む。例えば、「１～２」により表される範囲は、１以上２以下を意味し、１及び２を含む。本明細書において、上限及び下限は、いずれの組み合わせによる範囲としてもよい。
In this specification, the numerical range expressed by a lower limit value and an upper limit value, ie, "lower limit value to upper limit value" includes the lower limit value and upper limit value. For example, the range represented by "1 to 2" means 1 or more and 2 or less, and includes 1 and 2. In this specification, the upper limit and the lower limit may be any combination of ranges.
以下、本発明を実施例に基づいてより具体的に説明する。尚、本発明はこれらの実施例に限定されるものではない。
Hereinafter, the present invention will be described in more detail based on Examples. Note that the present invention is not limited to these examples.
下記の評価試験で使用した材料は以下のとおりである。
（Ａ）エルゴチオネイン：Ｌ－エルゴチオネイン１００％含有原料
（Ｂ）グルコサミン塩酸塩：グルコサミン塩酸塩１００％含有原料 The materials used in the evaluation test below are as follows.
(A) Ergothioneine: Raw material containing 100% L-ergothioneine (B) Glucosamine hydrochloride: Raw material containing 100% glucosamine hydrochloride
（Ａ）エルゴチオネイン：Ｌ－エルゴチオネイン１００％含有原料
（Ｂ）グルコサミン塩酸塩：グルコサミン塩酸塩１００％含有原料 The materials used in the evaluation test below are as follows.
(A) Ergothioneine: Raw material containing 100% L-ergothioneine (B) Glucosamine hydrochloride: Raw material containing 100% glucosamine hydrochloride
＜実施例１：エルゴチオネイン及びグルコサミン塩酸塩を含む組成物についての香味評価試験＞
エルゴチオネイン及びグルコサミン塩酸塩を含む組成物を調製し、官能評価に熟練したパネラー３名が官能評価を行った。
表１に示す量の上記（Ａ）及び（Ｂ）を混合して、試料１～９の組成物（エルゴチオネイン及びグルコサミン塩酸塩を含む組成物）を調製した。試料１～９の組成物中の（Ｂ）／（Ａ）の重量比（グルコサミン換算の（Ｂ）／（Ａ））を表１に示す。３名のパネラーがそれぞれ、調製した組成物の全量（例えば、試料１ではエルゴチオネイン１０ｍｇとグルコサミン塩酸塩１ｍｇの合計１１ｍｇ）を直接舌の上にのせて、エルゴチオネイン由来の苦味の強度、グルコサミン塩酸塩由来の異味の強度を以下の基準にしたがって評価した。 <Example 1: Flavor evaluation test for a composition containing ergothioneine and glucosamine hydrochloride>
A composition containing ergothioneine and glucosamine hydrochloride was prepared, and three panelists skilled in sensory evaluation performed sensory evaluation.
Compositions of Samples 1 to 9 (compositions containing ergothioneine and glucosamine hydrochloride) were prepared by mixing the amounts of (A) and (B) shown in Table 1. Table 1 shows the weight ratios of (B)/(A) ((B)/(A) in terms of glucosamine) in the compositions of Samples 1 to 9. Three panelists each placed the entire amount of the prepared composition (for example, in sample 1, 10 mg of ergothioneine and 1 mg of glucosamine hydrochloride, total 11 mg) on their tongues, and evaluated the intensity of bitterness derived from ergothioneine and the intensity of bitterness derived from glucosamine hydrochloride. The intensity of off-taste was evaluated according to the following criteria.
エルゴチオネイン及びグルコサミン塩酸塩を含む組成物を調製し、官能評価に熟練したパネラー３名が官能評価を行った。
表１に示す量の上記（Ａ）及び（Ｂ）を混合して、試料１～９の組成物（エルゴチオネイン及びグルコサミン塩酸塩を含む組成物）を調製した。試料１～９の組成物中の（Ｂ）／（Ａ）の重量比（グルコサミン換算の（Ｂ）／（Ａ））を表１に示す。３名のパネラーがそれぞれ、調製した組成物の全量（例えば、試料１ではエルゴチオネイン１０ｍｇとグルコサミン塩酸塩１ｍｇの合計１１ｍｇ）を直接舌の上にのせて、エルゴチオネイン由来の苦味の強度、グルコサミン塩酸塩由来の異味の強度を以下の基準にしたがって評価した。 <Example 1: Flavor evaluation test for a composition containing ergothioneine and glucosamine hydrochloride>
A composition containing ergothioneine and glucosamine hydrochloride was prepared, and three panelists skilled in sensory evaluation performed sensory evaluation.
Compositions of Samples 1 to 9 (compositions containing ergothioneine and glucosamine hydrochloride) were prepared by mixing the amounts of (A) and (B) shown in Table 1. Table 1 shows the weight ratios of (B)/(A) ((B)/(A) in terms of glucosamine) in the compositions of Samples 1 to 9. Three panelists each placed the entire amount of the prepared composition (for example, in sample 1, 10 mg of ergothioneine and 1 mg of glucosamine hydrochloride, total 11 mg) on their tongues, and evaluated the intensity of bitterness derived from ergothioneine and the intensity of bitterness derived from glucosamine hydrochloride. The intensity of off-taste was evaluated according to the following criteria.
（Ａ）エルゴチオネイン由来の苦味の評価基準
上記（Ａ）エルゴチオネインのみ（１０ｍｇ）の苦味の強度を５点とし（コントロール１）、エルゴチオネイン由来の苦味を感じない場合を１点として、１～５点（５段階）で評価した。
３名のパネラーの評価を集計し、平均値を表１に示す。
５点：エルゴチオネイン由来の苦味を強く感じる
４点：エルゴチオネイン由来の苦味を感じる
３点：エルゴチオネイン由来の苦味を少し感じる
２点：エルゴチオネイン由来の苦味をあまり感じない
１点：エルゴチオネイン由来の苦味を感じない (A) Evaluation criteria for bitterness derived from ergothioneine The above (A) The intensity of the bitterness of ergothioneine alone (10 mg) was scored as 5 points (control 1), and the case where no bitterness derived from ergothioneine was felt was scored as 1 point, ranging from 1 to 5 points ( Evaluation was made on a 5-point scale.
The evaluations of the three panelists were totaled, and the average value is shown in Table 1.
5 points: I strongly feel the bitterness derived from ergothioneine 4 points: I feel the bitterness derived from ergothioneine 3 points: I feel a little bitterness derived from ergothioneine 2 points: I do not feel the bitterness derived from ergothioneine very much 1 point: I do not feel the bitterness derived from ergothioneine
上記（Ａ）エルゴチオネインのみ（１０ｍｇ）の苦味の強度を５点とし（コントロール１）、エルゴチオネイン由来の苦味を感じない場合を１点として、１～５点（５段階）で評価した。
３名のパネラーの評価を集計し、平均値を表１に示す。
５点：エルゴチオネイン由来の苦味を強く感じる
４点：エルゴチオネイン由来の苦味を感じる
３点：エルゴチオネイン由来の苦味を少し感じる
２点：エルゴチオネイン由来の苦味をあまり感じない
１点：エルゴチオネイン由来の苦味を感じない (A) Evaluation criteria for bitterness derived from ergothioneine The above (A) The intensity of the bitterness of ergothioneine alone (10 mg) was scored as 5 points (control 1), and the case where no bitterness derived from ergothioneine was felt was scored as 1 point, ranging from 1 to 5 points ( Evaluation was made on a 5-point scale.
The evaluations of the three panelists were totaled, and the average value is shown in Table 1.
5 points: I strongly feel the bitterness derived from ergothioneine 4 points: I feel the bitterness derived from ergothioneine 3 points: I feel a little bitterness derived from ergothioneine 2 points: I do not feel the bitterness derived from ergothioneine very much 1 point: I do not feel the bitterness derived from ergothioneine
（Ｂ）グルコサミン塩酸塩由来の異味の評価基準
上記（Ｂ）グルコサミン塩酸塩のみ（１０ｍｇ）の塩味、舌に残る甘味、えぐみを伴う特有の異味の強度を５点とし（コントロール２）、グルコサミン塩酸塩由来の異味を感じない場合を１点として、１～５点（５段階）で評価した。
３名のパネラーの評価を集計し、平均値を表１に示す。
５点：グルコサミン塩酸塩由来の異味を強く感じる
４点：グルコサミン塩酸塩由来の異味を感じる
３点：グルコサミン塩酸塩由来の異味を少し感じる
２点：グルコサミン塩酸塩由来の異味をあまり感じない
１点：グルコサミン塩酸塩由来の異味を感じない (B) Evaluation criteria for off-taste derived from glucosamine hydrochloride Above (B) Glucosamine hydrochloride alone (10 mg) was given 5 points for the intensity of the characteristic off-taste accompanied by salty taste, sweetness that remains on the tongue, and acrid taste (Control 2). Evaluation was made on a scale of 1 to 5 (on a 5-point scale), with a score of 1 being that no off-taste derived from hydrochloride was felt.
The evaluations of the three panelists were totaled, and the average value is shown in Table 1.
5 points: I strongly feel the off-taste derived from glucosamine hydrochloride 4 points: I feel the off-taste from glucosamine hydrochloride 3 points: I feel a little off-taste from glucosamine hydrochloride 2 points: I don't really notice the off-taste from glucosamine hydrochloride 1 point : No unpleasant taste derived from glucosamine hydrochloride
上記（Ｂ）グルコサミン塩酸塩のみ（１０ｍｇ）の塩味、舌に残る甘味、えぐみを伴う特有の異味の強度を５点とし（コントロール２）、グルコサミン塩酸塩由来の異味を感じない場合を１点として、１～５点（５段階）で評価した。
３名のパネラーの評価を集計し、平均値を表１に示す。
５点：グルコサミン塩酸塩由来の異味を強く感じる
４点：グルコサミン塩酸塩由来の異味を感じる
３点：グルコサミン塩酸塩由来の異味を少し感じる
２点：グルコサミン塩酸塩由来の異味をあまり感じない
１点：グルコサミン塩酸塩由来の異味を感じない (B) Evaluation criteria for off-taste derived from glucosamine hydrochloride Above (B) Glucosamine hydrochloride alone (10 mg) was given 5 points for the intensity of the characteristic off-taste accompanied by salty taste, sweetness that remains on the tongue, and acrid taste (Control 2). Evaluation was made on a scale of 1 to 5 (on a 5-point scale), with a score of 1 being that no off-taste derived from hydrochloride was felt.
The evaluations of the three panelists were totaled, and the average value is shown in Table 1.
5 points: I strongly feel the off-taste derived from glucosamine hydrochloride 4 points: I feel the off-taste from glucosamine hydrochloride 3 points: I feel a little off-taste from glucosamine hydrochloride 2 points: I don't really notice the off-taste from glucosamine hydrochloride 1 point : No unpleasant taste derived from glucosamine hydrochloride
エルゴチオネイン由来の苦味の評価及びグルコサミン塩酸塩由来の異味の評価の平均値がいずれも４．０点未満の場合に、エルゴチオネインに由来する苦味及びグルコサミン塩酸塩に由来する異味が抑制されたと評価した。
When the average value of the evaluation of bitterness derived from ergothioneine and the evaluation of off-taste derived from glucosamine hydrochloride were both less than 4.0 points, it was evaluated that the bitterness derived from ergothioneine and the off-taste derived from glucosamine hydrochloride were suppressed.
グルコサミン塩酸塩を配合しない場合は、エルゴチオネインに由来する、舌を刺すような苦味が強く感じられた（コントロール１）。一方、グルコサミン塩酸塩のみの場合には、グルコサミン塩酸塩に由来する異味が強く感じられた（コントロール２）。（Ａ）エルゴチオネインに対する（Ｂ）グルコサミン塩酸塩（グルコサミン換算）の重量比（（Ｂ）／（Ａ））が０．２～１５０の範囲である試料２～７及び試料９では、エルゴチオネインに由来する苦味及びグルコサミン塩酸塩に由来する異味の両方が効果的に緩和された。
When glucosamine hydrochloride was not added, a bitter taste resulting from ergothioneine that stinged the tongue was strongly felt (Control 1). On the other hand, in the case of only glucosamine hydrochloride, the off-taste derived from glucosamine hydrochloride was strongly perceived (Control 2). In Samples 2 to 7 and Sample 9, in which the weight ratio ((B)/(A)) of (B) glucosamine hydrochloride (in terms of glucosamine) to (A) ergothioneine is in the range of 0.2 to 150, it is derived from ergothioneine. Both bitterness and off-taste derived from glucosamine hydrochloride were effectively alleviated.
When glucosamine hydrochloride was not added, a bitter taste resulting from ergothioneine that stinged the tongue was strongly felt (Control 1). On the other hand, in the case of only glucosamine hydrochloride, the off-taste derived from glucosamine hydrochloride was strongly perceived (Control 2). In Samples 2 to 7 and Sample 9, in which the weight ratio ((B)/(A)) of (B) glucosamine hydrochloride (in terms of glucosamine) to (A) ergothioneine is in the range of 0.2 to 150, it is derived from ergothioneine. Both bitterness and off-taste derived from glucosamine hydrochloride were effectively alleviated.
Claims (5)
- 下記の成分（Ａ）及び（Ｂ）：
（Ａ）エルゴチオネイン又はその塩、及び、
（Ｂ）グルコサミン類化合物、を含有し、
成分（Ａ）（エルゴチオネイン換算）に対する、成分（Ｂ）（グルコサミン換算）の重量比（（Ｂ）／（Ａ））が０．２～１５０である、経口組成物。 Ingredients (A) and (B) below:
(A) ergothioneine or a salt thereof, and
(B) contains a glucosamine compound,
An oral composition, wherein the weight ratio ((B)/(A)) of component (B) (in terms of glucosamine) to component (A) (in terms of ergothioneine) is 0.2 to 150. - グルコサミン類化合物は、グルコサミン、その誘導体及びそれらの塩からなる群より選択される少なくとも１種である、請求項１に記載の組成物。 The composition according to claim 1, wherein the glucosamine compound is at least one selected from the group consisting of glucosamine, derivatives thereof, and salts thereof.
- グルコサミンの誘導体は、グルコサミンの少なくとも１つの水酸基の水素原子及び／又はアミノ基の水素原子が、炭素数１～１０のアシル基及び／又はアルキル基に置換された化合物である、請求項２に記載の組成物。 According to claim 2, the glucosamine derivative is a compound in which at least one hydrogen atom of a hydroxyl group and/or a hydrogen atom of an amino group of glucosamine is substituted with an acyl group and/or an alkyl group having 1 to 10 carbon atoms. Composition of.
- 飲食品である、請求項１～３のいずれかに記載の組成物。 The composition according to any one of claims 1 to 3, which is a food or drink.
- 下記の成分（Ａ）及び（Ｂ）：
（Ａ）エルゴチオネイン又はその塩、及び、
（Ｂ）グルコサミン類化合物、
を含有する経口組成物において、
成分（Ａ）（エルゴチオネイン換算）に対する、成分（Ｂ）（グルコサミン換算）の重量比（（Ｂ）／（Ａ））を０．２～１５０に調整する、エルゴチオネイン又はその塩に由来する苦味及びグルコサミン類化合物に由来する異味を抑制する方法。
Ingredients (A) and (B) below:
(A) ergothioneine or a salt thereof, and
(B) glucosamine compound,
In an oral composition containing,
Bitterness and glucosamine derived from ergothioneine or its salt, which adjusts the weight ratio ((B)/(A)) of component (B) (glucosamine equivalent) to component (A) (ergothioneine equivalent) to 0.2 to 150. A method for suppressing off-flavors derived from similar compounds.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022114836 | 2022-07-19 | ||
| JP2022-114836 | 2022-07-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2024018955A1 true WO2024018955A1 (en) | 2024-01-25 |
Family
ID=89617787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2023/025650 WO2024018955A1 (en) | 2022-07-19 | 2023-07-12 | Oral composition, and method for suppressing bitterness derived from ergothioneine and off-flavor derived from glucosamine compound |
Country Status (2)
| Country | Link |
|---|---|
| TW (1) | TW202412842A (en) |
| WO (1) | WO2024018955A1 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002502881A (en) * | 1998-02-13 | 2002-01-29 | ニュートラマックス ラボラトリーズ，インコーポレイテッド | Agents and methods for protecting, treating, and repairing connective tissue |
| US20100151084A1 (en) * | 2008-12-15 | 2010-06-17 | Pepsico, Inc. | Unsaturated acids for fading protection of colors derived from natural sources used in beverage products |
| JP2012092085A (en) * | 2010-09-28 | 2012-05-17 | Oriza Yuka Kk | Anti-skin photoaging agent using coprinus comatus and extract thereof |
| US20120141611A1 (en) * | 2010-12-05 | 2012-06-07 | Oxis International Inc. | Methods and compositions using ergothioneine to treat a variety of health related factors |
-
2023
- 2023-07-12 WO PCT/JP2023/025650 patent/WO2024018955A1/en unknown
- 2023-07-14 TW TW112126319A patent/TW202412842A/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002502881A (en) * | 1998-02-13 | 2002-01-29 | ニュートラマックス ラボラトリーズ，インコーポレイテッド | Agents and methods for protecting, treating, and repairing connective tissue |
| US20100151084A1 (en) * | 2008-12-15 | 2010-06-17 | Pepsico, Inc. | Unsaturated acids for fading protection of colors derived from natural sources used in beverage products |
| JP2012092085A (en) * | 2010-09-28 | 2012-05-17 | Oriza Yuka Kk | Anti-skin photoaging agent using coprinus comatus and extract thereof |
| US20120141611A1 (en) * | 2010-12-05 | 2012-06-07 | Oxis International Inc. | Methods and compositions using ergothioneine to treat a variety of health related factors |
Also Published As
| Publication number | Publication date |
|---|---|
| TW202412842A (en) | 2024-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3000100C (en) | Method of producing mushrooms | |
| JPWO2006093267A1 (en) | Fermentation composition having immunomodulatory action | |
| KR20230152614A (en) | Composition for improving cognitive function speed | |
| JP2004315512A (en) | Functional composition | |
| WO2022230491A1 (en) | Composition for ameliorating or suppressing decline of kidney functions | |
| WO2024018955A1 (en) | Oral composition, and method for suppressing bitterness derived from ergothioneine and off-flavor derived from glucosamine compound | |
| JPH0937711A (en) | Health food | |
| WO2022230493A1 (en) | Composition for increasing leukocytes and/or basophils | |
| JP2003146887A (en) | Formulation and food and drink having nk cell- activating effect | |
| WO2024018956A1 (en) | Oral composition, and method for suppressing bitterness originating from ergothioneine or salt thereof and odor originating from chondroitin sulfate or salt thereof | |
| WO2024029393A1 (en) | Oral composition, and method for suppressing bitterness derived from ergothioneine or salt thereof and odor derived from milk-derived ceramide-containing material | |
| WO2023120367A1 (en) | Oral composition and method for suppressing bitterness derived from ergothioneine | |
| WO2024029392A1 (en) | Oral composition, and method for suppressing bitterness derived from ergothioneine or salt thereof | |
| WO2023120368A1 (en) | Oral composition, and method for suppressing bitterness derived from ergothioneine or salt thereof and odor derived from eicosapentaenoic acid | |
| WO2024172002A1 (en) | Vasodilation composition containing ergothioneine | |
| WO2023120376A1 (en) | ORAL COMPOSITION, AND METHOD FOR SUPPRESSING BITTERNESS DERIVED FROM ERGOTHIONEINE AND ODOR DERIVED FROM CEREAL OIL OR γ-ORYZANOL | |
| AU2022420208A1 (en) | Oral composition, and method for suppressing bitterness derived from ergothioneine or salt thereof and odor derived from docosahexaenoic acid | |
| WO2023090260A1 (en) | Composition for inhibiting histamine-n-methyltransferase | |
| WO2023120370A1 (en) | Oral composition and method for minimizing bitter taste resulting from ergothioneine or salt thereof and odor resulting from vitamin e | |
| WO2023120378A1 (en) | Oral composition, and method for suppressing bitterness derived from ergothioneine or salt thereof and smell derived from arachidonic acids | |
| JPH0881371A (en) | Hematopoietic function promoter | |
| KR20240048145A (en) | Antimicrobial composition comprising the extract of songhwa mushroom fruiting body | |
| CN111700920A (en) | Physiological function active agent and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23842880 Country of ref document: EP Kind code of ref document: A1 |